

Exploring the Potential of Asian Medicinal Plants in the Prevention and Treatment of Leukemia: A Comprehensive Ethnopharmacological Review

Maedeh Zolfaghari¹, Somayeh Zarezadeh² and Ali Akbar Ghotbi-Ravandi^{1*}¹ Department of Plant Sciences and Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran² Department of Applied Chemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran**Article Info****ABSTRACT****Article Type**
Review Article**Article History**Received: 12 February 2025
Accepted: 03 August 2025
© 2012 Iranian Society of Medicinal Plants.
All rights reserved.***Corresponding author**
a_ghotbi@sbu.ac.ir

The effectiveness of Asian herbal medications has been known since ancient times. Their impacts on people's lives are significant, and their efficacy has been demonstrated in various studies. These plants contain phytochemicals, such as antioxidants, in their essential oils or extracts, classifying them as anti-leukemic agents. One of the primary concerns in modern medicine is the search for new treatments and innovative preventive approaches to cancer. Leukemia stands among the 15 most frequent types of cancer. Due to its high mortality rate, further research should focus on treatment and especially prevention. Chemotherapy is the most common treatment for leukemia; however, it causes undesirable side effects. That is why the exploration of alternative strategies should be prioritized. A comprehensive literature search was conducted using the following keywords: anti-leukemic plants, leukemia prevention, and leukemia treatment. The main databases included Google Scholar, Springer Link, PubMed, ScienceDirect, and Elsevier. This review provides a list of 104 medicinal plant species used by Asian folk, with documented anti-leukemic properties. The plants mentioned in this paper contain various phytochemicals, such as flavonoids and alkaloids. Numerous *in vitro* and *in vivo* studies have demonstrated the promising effects of these plant extracts against leukemic cell lines. They help prevent and treat leukemia by inducing apoptosis and cell death, reducing cell viability, suppressing cell invasion, and targeting specific leukemic cell lines through various bioactive compounds like chlorogenic acid, xanthochymol, and berbamine. They also inhibit angiogenesis and disrupt cancer cell proliferation through mechanisms such as vascular endothelial growth factor (VEGF) suppression and STAT3 inhibition. The results of the current review could be applied in the development of a new generation of anti-leukemia drugs with minimal drawbacks.

Keywords: Anti-cancer, Herbal medicine, Leukemia, Plant secondary metabolites**How to cite this paper**

Zolfaghari, M., Zarezadeh, S., Ghotbi-Ravandi, A.A. Exploring the Potential of Asian Medicinal Plants in the Prevention and Treatment of Leukemia: A Comprehensive Ethnopharmacological Review. Journal of Medicinal Plants and By-products, 2026; 15(2):153-167. doi: 10.22034/jmpb.2025.368615.1896

INTRODUCTION

Cancer is one of the main global public health issues and the second leading cause of mortality worldwide [1]. The incidence of cancer is influenced by numerous factors such as age, genetics, smoking, alcohol consumption, obesity, ultraviolet (UV) radiation, and certain viruses [2]. While certain factors, such as genetics, cannot be changed, the occurrence of this disease can be significantly reduced by managing other risk factors. Studies show that in high-income countries, up to 80% of cancer cases can be prevented by addressing environmental factors and lifestyle choices, including nutrition [3].

Phytochemicals are small molecules found in fruits and vegetables and have demonstrated anti-cancer properties in both *in vitro* and *in vivo* studies [4]. These compounds are synthesized by plants to cope with unfavorable environmental conditions, such as biotic and abiotic stresses [5]. Common examples of phytochemicals include polyphenols, carotenoids, phytosterols, flavonoids, and alkaloids [6]. Quercetin, a prominent flavonoid in fruits and vegetables, has been reported to modulate almost all hallmarks of cancer [7]. Other phytochemicals, like alkaloids, have anti-proliferative, antibacterial, and antioxidant potential, and have the potential to be used in drug development [8].

Currently, chemotherapy, radiotherapy, immunotherapy, and even surgical removal are applied to treat cancer; however, these treatments may result in diverse side effects [9], such as skin diseases, cardio-toxicity, headaches, hair loss, and neurological disorders [9, 10]. Additionally, cancer can metastasize from its primary site to different organs [11]. Metastasis is the cause of over 90% of deaths in all cancer types since conventional treatments are often ineffective in such cases [12]. Therefore, prioritizing prevention over treatment is essential.

Among various types of cancer, leukemia stands out with 437,033 cases diagnosed globally and approximately 309,006 deaths recorded in 2018 [13], making it a significant concern in the medical field. Several environmental factors, such as ionizing radiation [14, 15], chemical exposures [16, 17], maternal exposures [17–19], and air pollution [18], have been identified as contributors to leukemia development. However, identifying and quantifying environmental risk factors remains challenging due to difficulties in exposure assessment, the presence of multiple confounding factors, and the need for large study populations to detect effects from low-level exposures [14]. Genetic and inherited factors are also estimated to contribute to approximately 10% of childhood leukemia cases [20, 21]. Genetic and inherited conditions, including inherited syndromes [16, 22], genetic

mutations and abnormalities [23], as well as inherited genetic susceptibility, are associated with increased leukemia risk [20, 21]. Lifestyle and personal factors, on the other hand, have been associated with increased leukemia risk. Smoking, diet and nutrition [24, 25], body composition and physical activity [23], prior medical treatments, such as previous chemotherapy treatment for other cancers, can increase leukemia risk [26] (Fig. 1).




Fig. 1 Factors affecting leukemia risk. Leukemia can be broadly classified into two main categories: acute leukemia (AL) and chronic leukemia (CL).

AL progresses rapidly and is characterized by severe clinical signs, whereas CL develops more slowly and tends to have a milder initial presentation. The four primary types of leukemia fall under these two categories: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML) [27]. Notably, CLL and CML are less common among Asians compared to European populations, where their incidence is higher [28, 29]. This disparity may be influenced not only by genetic factors but also by dietary habits and the use of traditional herbal remedies in Asian cultures, which may offer a protective effect against cancer [30, 31]. Asian medicinal plants, in particular, have long been recognized for their potent therapeutic properties.

Given the potential of many Asian medicinal herbs to prevent or possibly be effective in treating leukemia patients [32], this review compiles a list of medicinal plants used in traditional Asian medicine with anti-leukemic effects. These plants can be used as traditional medicines or dietary supplements. Moreover, future studies can explore their potential for developing a generation of anti-leukemia drugs.

MATERIALS AND METHODS

A comprehensive literature search was conducted, and the information from 270 articles (reviews and research articles) has been gathered in this review. The main relevant keywords used in finding results were: anti-leukemic plants, leukemia prevention, leukemia treatment, and Asian anti-leukemic herbal medicine. The results and the names of the 104 plant species are combined in a single table, which describes their usage in Asian traditional medicine and their mechanisms of action. The challenges in gathering this information were that not all plants have been fully

investigated, and further research is needed to understand their exact mechanisms. The main databases used for this comprehensive search were Google Scholar, Springer Link, PubMed, ScienceDirect, and Elsevier.

Types of Leukemia

Acute Lymphocytic Leukemia (ALL)

This type of leukemia is characterized by a disruption in the differentiation of early lymphoid progenitors, leading to the accumulation of immature lymphoblasts [33]. The most common symptoms include fever, fatigue, or purpuric rash [34]. Aberrant DNA methylation of multiple CpG islands (CGI) in ALL has been identified as a prevalent factor contributing to a poor prognosis [33]. ALL cells can originate from either B or T cells [35]. Notably, in T-cell ALL, only a few molecular abnormalities have been identified, whereas B-lineage ALL often involves additional genetic abnormalities that can influence the clinical course of the disease [36].

Folic acid deficiency is considered a risk factor for adult ALL [37], potentially related to chromosome breaks that increase the risk of folate-deficiency-associated cancers [37]. ALL in adults often involves the central nervous system (CNS) [38]. CNS involvement occurs in 3-5% of patients at diagnosis, rising to 30-40% at relapse, with CNS relapse being a major cause of treatment failure [39-41]. Leukemic cells infiltrate the CNS through adhesion molecules (VLA-4, ICAM-1) and integrin-mediated migration [42, 43]. While some patients present with neurological symptoms such as headaches, seizures, or cranial nerve deficits, many remain asymptomatic, necessitating lumbar puncture (LP) for detection [44]. It is recommended that all newly diagnosed patients with ALL undergo routine LP testing [38].

LP classifies CNS involvement as CNS1 (<5 white blood cells (WBCs)/ μ L, no blasts), CNS2 (<5 WBCs/ μ L with blasts), or CNS3 (\geq 5 WBCs/ μ L with blasts or cranial nerve involvement) [45]. Flow cytometry enhances sensitivity over conventional cytology, improving detection rates from 30% to 65% [41, 46]. CNS3 status is associated with poor outcomes (50% 5-year survival vs. 80% for CNS1), underscoring the importance of early CNS-directed therapy [39, 47].

Acute myeloid leukemia (AML)

AML ranks among the common leukemias in adults [48]. AML affects myeloid, erythroid, megakaryocytic, and monocytic cells [49], and typically presents with symptoms such as fatigue, dizziness, bone pain, and extreme weakness [50].

It is characterized by poorly differentiated or abnormal cells and clonal transformation within the hematopoietic system [49, 51].

In this hematopoietic disorder, mutant cells undergo changes that result in increased turnover and proliferative capacity, as well as altered hematopoietic differentiation [52]. Mutations can occur in various genes such as *NPM1*, *CEBPA*, *RUNX1*, *KIT*, *NRAS*, *FLT3-ITD*, *TP53*, *TET2*, *KMT2A-PTD*, *ASXL1*, *DNMT3A*, *IDH1*, and *IDH2* [51]. The most frequent mutation occurs in the *NPM1* gene in about 25 to 35 percent of patients, and it is often associated with other mutations in genes like *TET2*, *FLT3-ITD*, *DNMT3A*, *IDH1*, and *IDH2* [51]. Unlike ALL, AML is not substantially influenced by folic acid deficiency, as AML is not affected by the polymorphism [37]. Effective chemotherapy for AML, particularly in older patients, remains a significant challenge, with a median survival of 5 to 10 months in this demographic [51]. However, in patients aged 60 or younger,

AML can be cured in 35%–40% of cases with intense induction therapy and consolidation, often followed by allogeneic stem cell transplantation [51, 53]. Notably, the treatment of AML can lead to long-term side effects, including chronic fatigue and cognitive impairment, which may impact the quality of life for survivors [53].

Chronic Myelocytic Leukemia (CML)

CML accounts for approximately 20% of all leukemia cases [54, 55]. It is characterized by high WBC counts and extramedullary hematopoiesis (EMH), which causes spleen enlargement. These abnormalities result from a (9; 22) chromosomal translocation that creates the BCR-ABL fusion oncoprotein [54]. This genetic swap between chromosomes 9 and 22 produces the shorter Philadelphia chromosome [56]. The resulting fusion proteins (p210 or p185) lead to abnormal kinase activity [57–59], causing excessive proliferation of WBC [60]. Targeting BCR-ABL is therefore a key treatment strategy [56].

Accurate molecular and cytogenetic analyses are crucial for selecting the most effective treatment [61]. CML is often diagnosed during the chronic phase when it can be effectively managed with relatively low-toxicity drugs or bone marrow transplant [54].

In the chronic phase, lower quantities of BCR-ABL-positive stem cells gradually multiply while still producing normal blood cells (except T-cells)[62]. Several studies suggest that CML has a lower incidence in Asian and Middle Eastern countries compared to Western countries [28, 63], indicating that genetics or environmental factors, particularly diet, should be explored for a viable solution.

Chronic Lymphocytic Leukemia (CLL)

CLL is one of the most common forms of leukemia, representing 1.1% of all cancers in 2021. It predominantly affects elderly patients, with only 9.1% of cases occurring in individuals younger than 45 years old [64]. In its early stages, CLL symptoms may be vague, but signs such as an enlarged spleen, bone marrow failure, or swollen lymph nodes indicate the progression of the disease [65]. Genetic abnormalities play a key role in CLL development. Approximately 80% of patients carry at least one of four chromosomal changes: trisomy 12, deletions in 13q14.3, 11q22.3, or 17p13.1 [64, 66]. The 17p13.1 deletion, which disrupts the *p53* tumor suppressor gene, is rare at diagnosis but becomes more frequent as the disease advances. This deletion is particularly concerning because it is linked to chemotherapy resistance and poorer treatment outcomes [64, 67, 68]. CLL arises from abnormal CD5⁺/CD19⁺ B lymphocytes that weaken immune function [68]. Diagnosis involves blood tests, microscopic examination of blood smears, and immunophenotyping to detect these atypical B cells [64]. Interestingly, CLL is the most common form of leukemia in European countries, while Asia has one of the lowest age-adjusted incidences [69].

Traditional use of Plants in Cancer Treatment

Current cancer therapies like chemotherapy, immunotherapy, surgery, or radiation, while effective, often cause serious side effects such as heart toxicity, alopecia, skin disease, oral and stomach ulcers, epithelial layer destruction, neural problems, or bone marrow suppression [10]. While medicinal plants have demonstrated significant potential in cancer prevention and treatment, they cannot replace modern therapies. Instead, they

may serve as complementary adjuncts to conventional treatments, helping to mitigate side effects or enhance efficacy.

Ethnomedicine, which refers to the use of medication in different cultures and examines innovative local ideas and behaviors related to disease treatment and health improvement [70], can be used as a source of inspiration for next-generation drugs, as a huge number of today's useful therapies are derived from folk medicine [71]. The use of plants for disease treatment and combating infections has a long-term history [72], and has been addressed in numerous studies [73, 74]. Some studies have discovered that Chinese folk medicine plays an important role in cancer treatment, such as in skin cancer [75]. In Korea, traditional medicine is still used by licensed traditional doctors under the supervision of the Ministry of Health and Welfare of Korea [76].

Different species of plants are used traditionally in the treatment of various diseases, including cancer. For example, species of *Acacia* Mill. have been used for treating different types of cancer, such as mouth, bone, and skin cancers [77]. However, while these natural compounds show promise, they should be integrated thoughtfully into cancer care, ensuring they support, rather than replace, evidence-based medical treatments.

The Role of Plants and Plant Metabolites in the Prevention and Treatment of Leukemia

The rising number of cancer cases and the adverse effects of conventional treatments have prompted researchers to explore medicinal plants as an emerging and promising source of anti-cancer compounds [10]. Plant-derived compounds serve as a valuable source of pharmaceutical agents for various human diseases [78]. Moreover, the undeniable role of a diet rich in fruits and vegetables in reducing cancer risk underscores the potential of plant-based therapies [79].

Numerous plant species have exhibited anti-leukemic properties in various ways, including inducing apoptosis and cell death, reducing viability in leukemic cells, and suppressing cell invasion or cytotoxicity [68, 78, 80, 81]. *Piper betle* L., as a traditional medicinal plant in Southeast Asia, has been extensively studied for its anti-microbial, antioxidant, and chemopreventive effects [82]. The leaves of *P. betel*, often chewed fresh or dried [83], contain compounds such as tannins, hydroxychavicol, and eugenol [84]. Extracts from the leaves have demonstrated an inhibitory effect against the growth of human CML in xenograft models [82]. Chlorogenic acid (Chl) extracted from *P. betel* leaves effectively targets the BCR-ABL-positive K562 cells (*in vitro*); however, it has no effects on the viability and growth of BCR-ABL-negative lymphocytic and myeloid cell lines or primary CML cells [57]. Moreover, sodium chlorogenate (NaChl) extracted from leaves exhibited a destructive effect on BCR-ABL positive KU812 and KCL22 leukemic cell lines (*in vitro*) [57]. NaChl showed a higher efficacy in killing K562 cells compared to Chl [57].

Garcinia indica (Thouras) Choisy (Fig. 2), a medicinal plant native to India, has shown remarkable inhibitory activity and apoptosis induction in both CML and AML cells. In CML, overexpression of vascular endothelial growth factor (VEGF) and enhanced angiogenesis are common [85]. While xanthochymol (from *G. indica*) decreases cell invasion, VEGF secretion, and metalloprotease production in both CML and AML [80], xanthohumol (from hops) exerts similar effects but through distinct pathways. Xanthohumol inhibits the angiogenic process by suppressing VEGF secretion via AKT/NF- κ B blockade [85].

Table 1 Asian medicinal plants, their phytochemicals, and their mechanisms of action in leukemia treatment or prevention.

Number	Plant scientific name	Origin/grows in	Plant material/ compound(s)	Function	Reference(s)
1	<i>Aglaia leptantha</i> Miq.	South East Asia and tropical regions of East Asia	Silvestrol	Produces TGI and induces cell death in B-leukemia cells. Affects CLL, ALL, and P388.	[68, 91]
2	<i>Alhagi pseudalhagi</i> (M.Bieb) Desv. ex Shap.	Iran	Extracts from aerial parts	Acts against K562 (AML) and Jurkat tumor cell lines (T cell leukemia).	[11, 71]
3	<i>Allamanda cathartica</i> L.	South East Asia	Allamandin derivatives	Acts against the P388 leukemia in mice (<i>in vivo</i>).	[94, 96]
4	<i>Alstonia scholaris</i> (L.) R.Br.	Southern China, tropical Asia, India	Extract of stem bark	Has an anti-cancer effect on Dalton's lymphoma ascites (DLA) cells in culture.	[95, 97]
5	<i>Alstonia venenata</i> R.Br.	Tropical regions of Asia	Leaf extract	Has cytotoxic and antioxidant effects.	[95, 97, 98]
6	<i>Aphanamixis polystachya</i> (Wall.) R.Parker (syn. <i>Amoora rohituka</i> (Roxb.) Wight & Arn.)	South Asia	Amooranin (triterpenic acid) from bark	Has a cytotoxic effect against multidrug-resistant leukemia.	[99]
7	<i>Annona glabra</i> L.	Asia	Seed, leaf, and pulp extracts	Has cytotoxic activity against a leukemia cell line and its multidrug-resistant-derived cell line. Seed extracts induce apoptosis and necrosis in CEM and CEM/VLB cell lines and upregulate the expression of cyclin kinase inhibitors, leading to cell arrest at the G0/G1 phase. The most potent extract is derived from seeds.	[78]
8	<i>Arctium lappa</i> L.	Asia	Shoot extract	Acts against K562 (AML) and Jurkat tumor cell lines (T cell leukemia).	[71, 100]
9	<i>Arctium lappa</i> L.	Asia	Root extract	Induces mitochondrial-mediated caspase-dependent apoptosis in Jurkat human leukemic T cells and cell death.	[100, 101]
10	<i>Artemisia annua</i> L.	China	Leaf extract, artemisinin	Artesunate has anti-leukemic activity in AML. Kills human leukemia cells.	[102–105]
11	<i>Artemisia argyi</i> H.Lév. & Vaniot	South East Asia	Plant extract (scopoletin and isocopoletin)	Acts against P388 murine leukemia cell line. Has repressive effects against CCRF-CEM human leukemia cells.	[106, 107]
12	<i>Astragalus trimestris</i> L. (syn. <i>Astragalus membranaceus</i> Moench)	China, Asia	Lectin from root	Induces apoptosis in CML cells (K562).	[108–110]
13	<i>Barleria prionitis</i> L.	South Asia	Leaf extract	Has cytotoxicity against THP-1 (AML cell line).	[111–114]
14	<i>Berberis amurensis</i> Rupr.	Asia	Berberamine	Causes apoptosis in Gleevec-sensitive and -resistant Ph+ CML cells.	[86]
15	<i>Bidens pilosa</i> L. (syn. <i>Bidens Pilosa</i> var. <i>minor</i> (Blume) Sherff)	Asia	Whole plant extract	Acts against L1210, P3HR1, Raji, U937, and K562 leukemic cell lines.	[115, 116]
16	<i>Blumea balsamifera</i> (L.) DC.	Asia	Flavonoid quercetin	Enhances TRAIL activity in human leukemia cells, has anti-proliferative activity, and induces apoptosis.	[117, 118]
17	<i>Blumea lacera</i> (Burm.f.) DC.	Bangladesh and India	Dried plant	Acts against K562, U937, L1210, and P3HR1 leukemic cell lines.	[99, 119]
18	<i>Boswellia sacra</i> Flück.	Asia	AKBA (acetyl-11-keto- β -boswellic acid) and KBA (11-keto- β -boswellic acid)	Has antimicrobial activity. Inhibits the cell growth and proliferation by inhibiting topoisomerase I and IIa.	[120–122]
19	<i>Boswellia serrata</i> Roxb.	Asia especially India	Triterpenediol (TPD)	Induces apoptosis in human HL-60 leukemic cells by producing oxidative stress in cancer cells.	[111, 113, 123, 124]
20	<i>Calluna vulgaris</i> (L.) Hull	Asia	Ursolic acid from flowers	Has anti-proliferative activity against HL-60 leukemic cells <i>in vitro</i> .	[125–127]
21	<i>Calotropis procera</i> (Aiton) W.T.Aiton	South Asia	Extract of stem	Has cytotoxicity against human leukemia HL-60 cell line.	[99]
22	<i>Calotropis procera</i> (Aiton) W.T.Aiton	India	Bufalin, Digoxin	Induces apoptosis in HL-60, THP-1, K562, U937 and ML1 cell lines (<i>in vitro</i>).	[128]
23	<i>Camellia sinensis</i> (L.) Kuntze	East and South East Asia	Leaf aqueous extract	Decreases the viability of AML cells in humans (HL-60) and mice (C1498).	[31, 52, 111]
24	<i>Cannabis sativa</i> L.	Asia	Metallic nanoparticles, especially gold nanoparticles from the leaves	Acts against lymphoblastic leukemia cells and acute T cell leukemia.	[129, 130]

25	<i>Carapichea ipecacuanha</i> (Brot.) L.Andersson (syn. <i>Cephaelis acuminata</i> H.Karst.)	Asia	Alkaloids	Acts against P388 and L1210 leukemia cell lines.	[111, 131]
26	<i>Catharanthus roseus</i> (L.) G.Don	China and Malaysia	Vinblastine, vincristine, vinflunine, catharanthine	Acts as an anti-proliferative and anti-cancer agent and induces apoptosis in Jurkat cells and K562.	[10, 86, 132]
27	<i>Cephalotaxus harringtonii</i> (Knight ex. J.Forbes) K.Koch (syn. <i>Cephalotaxus harringtonii</i> var. <i>drupacea</i> (Siebold & Zucc.) Koidz.)	East Asia	Alkaloids harringtonine, homoharringtonine, and isoharringtonine	Acts against myeloid leukemias.	[111, 131, 133]
28	<i>Cichorium intybus</i> L.	Iran	Shoot extract	Acts against K562 (AML) and Jurkat tumor cell lines (T cell leukemia).	[11, 71]
29	<i>Citrus hystrix</i> DC.	Asia	Crude extracts and essential oils from the leaves	Has cytotoxic and anti-proliferative activity against the murine leukemia (P388) cell lines.	[134, 135]
30	<i>Clausena lansium</i> (Lour.) Skeels	South East Asia	Stem	Has cytotoxic activity against K562 cell line.	[136]
31	<i>Clinacanthus nutans</i> (Burm.f.) Lindau	Asia	Fresh leaves extract	Acts against K562 cell line.	[136]
32	<i>Combretum caffrum</i> Kuntze	Asia	CA4P	Acts against ALL and CLL. Induces cell death by mitotic catastrophe in human B-lymphoid tumors.	[8, 92]
33	<i>Coptis chinensis</i> Franch.	China	Rhizome (rhizoma coptidis)	The alkaloid berberine downregulates telomerase activity and nucleophosmin/B23, resulting in apoptosis in HL-60 human leukemia cell lines.	[102]
34	<i>Coscinium fenestratum</i> (Gaertn.) Colebr.	Asia	Berberine	Has cytotoxic activity against HL-60 leukemia cells.	[137, 138]
35	<i>Cosmos caudatus</i> Kunth	South East Asia	Ethanol extract	Acts against P388 murine leukemia cell line.	[106]
36	<i>Curcuma longa</i> L.	Asia	Curcumin	Acts against K562 cell line in human CML.	[86, 139]
37	<i>Daucus carota</i> L.	West Asia	Extract of umbels and fruits	Has a high cytotoxic effect on 11 AML cell lines (HL-60, U937, ML1, ML2, Mono-Mac-1, Mono-Mac-6, KG-1, MV-4-11, TF1-vRaf, TF1vSrc, and TF1HaRas).	[48, 140]
38	<i>Dracocephalum kotschy</i> Boiss.	South West Asia especially Iran	Flavonoid aglycones, naringenin, cirsimaritin, penduletin apigenin, luteolin, isokaempferide, xanthomicrol, calycoperin	Has anti-proliferative activities against several cancer cell lines including human HL-60 leukemia.	[141–143]
39	<i>Dracocephalum kotschy</i> Boiss. in combination with <i>Peganum harmala</i> L.	<i>Peganum harmala</i> grows in Central Asia and Middle East	Flavonoids luteolin, naringenin, apigenin, isokaempferide, cirsimaritin, penduletin, xanthomicrol, and calycoperin	Acts against HL-60 cell lines.	[141, 143, 144]
40	<i>Eleutherococcus</i> spp. Maxim.	Eastern Asia	Roots and leaves	Exhibits cytotoxic effect towards leukemic HL-60 cells. The root extract of <i>E. divaricatus</i> shows the highest proapoptotic and cytotoxic effect on the HL-60 cell line.	[145, 146]
41	<i>Etilingera elatior</i> (Jack) R.M.Sm.	South East Asia	Flowershoots	Inhibits cell proliferation in MV4-11 and K562 leukemic cells, mainly through apoptosis in a dose-dependent manner.	[147, 148]
42	<i>Euphorbia hirta</i> L.	Asia	Powder and liquid extract	Acts against HL-60 leukemic cells <i>in vitro</i> (AML).	[111, 113, 149]
43	<i>Euphorbia kansui</i> Liou ex S.B.Ho	China	Diterpenes kansuinines and ingerols from root	Has anti-tumor activity in different types of cancer such as leukemia.	[150, 151]
44	<i>Eurycoma longifolia</i> Jack	Malaysia, Vietnam, Thailand, Myanmar, Cambodia, and Indonesia	Bark, stem, and root	Eurycomanone and eurycomanol have cytotoxic effects against murine lymphocytic leukemia (Jurkat and K562 cell lines).	[55]
45	<i>Garcinia hanburyi</i> Hook.f.	Central and South East Asia	Gambogic acid	Has cytotoxic activity against K562 cell line. Downregulates mRNA levels in HL-60 and Jurkat cells, including apoptosis.	[92, 152]
46	<i>Garcinia indica</i> (Thouars) Choisy	India	Fruit extract	Garcinol induces apoptosis and growth inhibition in both AML and CML, especially in the	[80, 102]

47	<i>Garcinia mangostana</i> L.	Southeast Asia, South West India	Xanthones	human HL-60 leukemia cell line. Inhibits the cell growth in human leukemia HL-60, K562, U937, and NB-4 cell lines.	[152, 153]
48	<i>Getonia floribunda</i> Roxb. (syn. <i>Calycopteris floribunda</i> (Roxb.) Lam. ex Poir.)	Asia	5,30-dihydroxy-3,6,7,8,40 - pentamethoxy-flavone and 30 -amino-5-hydroxy-3,6,7,8,40 – penta-methoxyflavone	Has anti-proliferative activity against HL-60, HL-60R, and K-562 leukemia cell lines.	[154]
49	<i>Glycine max</i> (L.) Merr.	South East Asia	Genistein	Causes apoptosis in Jurkat cells. Affects the proliferation and differentiation of human U937 leukemic cell line.	[31, 155–158]
50	<i>Glycyrrhiza glabra</i> L.	Iran	Shoot extract	Acts against K562 (AML) and Jurkat tumor cell lines (T cell leukemia).	[11, 71]
51	<i>Gymnanthemum amygdalinum</i> (Delile) Sch.Bip. (syn. <i>Vernonia amygdalina amygdalina</i> Delile)	Asia	Root extract	Has a cytotoxic effect against primary cells harvested from AML and ALL patients.	[136, 159]
52	<i>Hibiscus cannabinus</i> L.	Asia	Seed oil	Induces cell death in human leukemia HL-60 and K562 cell lines and murine myelomonocytic WEHI-3H cells through induction of apoptosis.	[32, 160]
53	<i>Houttuynia cordata</i> Thunb.	China	Crude extract from stem and leaf	Acts against U937, HL-60 and Molt4 leukemic cell lines.	[116, 161]
54	<i>Hyptis suaveolens</i> (L.) Poit.	Asia	Leaf extract	Inhibits the viability of Jurkat cells and human T-leukemia cells.	[81]
55	<i>Ixeris chinensis</i> ((Thunb.) Nakai	China	Extract	Inhibits the growth of leukemia cells.	[119, 162]
56	<i>Jatropha curcas</i> L.	Asia and Middle East	α -amyrin and taraxerol (triterpenes) and the diterpenes: jatrophol, jatrofolone A, B, and phorbols	The seed powder of the plant, when combined with honey, has been traditionally used to treat tumors. The plant extract shows strong inhibitory activity against P388 lymphocytic leukemia (<i>in vitro</i> and <i>in vivo</i>).	[163, 164]
57	<i>Jatropha gossypifolia</i> L.	South Asia	Lignans, falodone, and jatrophone	Has cytotoxic and anti-proliferative effect against P338 lymphocytic leukemia cell line.	[99]
58	<i>Kaempferia galanga</i> L.	South East Asia	Rhizome	Has anti-proliferative activity against CCRF-CEM leukemia cells.	[165, 166]
59	<i>Kaempferia parviflora</i> Wall. ex Baker	South East Asia	Ethanollic extract	Exhibits cytotoxicity against U937 cells (in a dose- and time-dependent manner). Has an anti-apoptotic role at low concentrations but induces apoptosis at high doses (activating caspase-3 at high doses).	[167, 168]
60	<i>Lavandula angustifolia</i> ssp. <i>angustifolia</i> (syn. <i>Lavandula officinalis</i> Chaix)	South West Asia to India	Essential oil	Induces apoptosis in HL-60 leukemic cells (in a dose-dependent manner).	[111, 169]
61	<i>Medicago sativa</i> L.	China	Flavonoids medicarpin and millepurpan	Medicarpin and millepurpan induce apoptosis and overcome multidrug resistance in P388 leukemic cells. Has anti-proliferative activity against the DU-145 cell line.	[71, 90, 170–174]
62	<i>Mentha longifolia</i> (L.) L.	Iran	Shoot extract	Acts against K562 (AML) and Jurkat tumor cell lines (T-cell leukemia).	[11, 71, 121]
63	<i>Momordica charantia</i> L.	Asia	Ripe fruit Leaf extract Plumericin (lactone)	Has <i>In vitro</i> anti-leukemic activity. Inhibits the proliferation of human HL-60 leukemia cell line.	[175, 176]
64	<i>Moringa oleifera</i> Lam.	Asia especially North Western India	Quercetin	Inhibits the proliferation of K562 and NB4 cell lines. Shows anti-tumor activity and is active against leukemia cells <i>in vitro</i> , inhibiting the viability of AML and ALL cells.	[94, 95, 177]
65	<i>Morus alba</i> L.	Eastern and Central China	Roots	Albanol A acts against HL-60 human leukemia cell line.	[102, 178]
66	<i>Ocimum basilicum</i> L.	Tropical and subtropical regions of Asia	Extract from leaves Shoot extract Essential oil	Has anti-proliferative and anti-cancer activity in the murine P388 leukemia cell line.	[121, 179, 180]
67	<i>Olea europaea</i> L.	Asia	Leaf extract	Inhibits cell growth in HL-60 human promyelocytic leukemia and proliferation in Jurkat.	[121, 181]
68	<i>Pereskia sacharosa</i> Griseb.	Asia	Triterpenes, flavonoid,	Inhibits proliferation in MV4-11 and K562 leukemic cells, mainly through apoptosis in a	[136, 147, 182]

			saponin, and tannins from leaves	dose-dependent manner.	
69	<i>Phaleria macrocarpa</i> (Scheff.) Boerl.	South Asia	Fruit extract	Gallic acid in the fruit extract induces apoptosis in leukemic cell lines.	[102, 183]
70	<i>Phaleria macrocarpa</i> (Scheff.) Boerl.	South Asia	Benzophenone glucoside compound from bark	Has an inhibitory effect on L1210 leukemic cell line (mouse).	[184]
71	<i>Phyllanthus niruri</i> L.	South and South East Asia	Lignans	Has cytotoxic effect on K562 cells.	[111, 113, 185, 186]
72	<i>Piper betle</i> L. (syn. <i>Piper betel</i> Blanco)	South East Asia especially India	Extract of whole plant	Inhibits the growth of human chronic myelogenous leukemia in xenograft models.	[57, 82, 84]
			Leaf extract (tannins, Chl, NaChl)	Chl, acts against K562 leukemic cell line. NaChl, acts against KU812 and KCL22 leukemic cell lines.	
73	<i>Plantago asiatica</i> L.	Central Asia	Whole plant extract	Inhibits the proliferation of K562, U937, P3HR1, HL-60, and CCRF-CEM leukemic cells.	[187]
74	<i>Plantago major</i> L.	Central Asia	Allantoin, aucubin, ursolic acid, flavonoids, asperuloside	Has anti-proliferation, cytotoxicity, and growth inhibition effects on MCF-7, MDAMB-231, HelaS3, A549, KB, THP-1, and AML cells.	[10, 187, 188]
75	<i>Platycodon grandiflorus</i> (Jacq.) A.DC.	China	Roots	Platycodin D (a triterpene saponin) induces cell death and apoptosis in the human U937 cell line.	[102]
76	<i>Prunella vulgaris</i> L.	North Eastern Asian countries such as Korea, China, and Japan	Ursolic acid	Inhibits lipoxygenase and cyclooxygenase in HL-60 leukemic cell line.	[126, 189]
			DHURS (2 α ,3 α -dihydroxyurs-12-en-28-oic acid)	Induces apoptotic DNA fragmentation in Jurkat T cells in human acute leukemia.	
77	<i>Psychotria serpens</i> L.	Asia	Ursolic acid	Has a cytotoxic effect against HL-60 leukemic cells.	[126, 190, 191]
78	<i>Punica granatum</i> L.	Asia	Peels	The peels of the plant inhibit cell proliferation in MV4-11 and K562 leukemic cells, mainly through apoptosis in a dose-dependent manner.	[147, 192, 193]
			Juice and peels	The juice and peels of the plant promote apoptosis in human HL-60 leukemia cells.	
			Seeds/punicic acid	Punicic acid from seeds has cytotoxic effects in leukemia cells via lipid peroxidation.	
79	<i>Rheum ribes</i> L.	Iran	Shoot extract	Acts against K562 (AML) and Jurkat tumor cell lines (T-cell leukemia).	[11, 71]
80	<i>Rubus parvifolius</i> L.	Traditional Chinese herb	Saponins	Causes apoptosis and changes in cell cycle checkpoints in human CML cells.	[87]
81	<i>Salvia miltiorrhiza</i> Bunge	Asia	Cryptotanshinone (CPT) from roots	Induces apoptosis in tumor cells <i>in vitro</i> or inhibits tumor cell growth. Causes cell cycle arrest in the G1 phase through downregulation of cyclin D1 expression by CPT. Inhibits proliferation of human glioma cells by suppressing STAT3 signaling.	[158, 194]
			15,16-Dihydrotanshinone (DHTS)	Causes apoptosis in human AML type 3 (HL-60 cells). Inhibits the proliferation of K562 human CML.	
82	<i>Satureja bachtiarica</i> Bunge	Iran	Shoot extract	Induces apoptosis and has strong inhibitory activity against Jurkat tumor cells (200 μ g/ml, >80% inhabitation) and the K562 cell line (200 μ g/ml, >50% inhabitation).	[11, 71, 195]
83	<i>Satureja hortensis</i> L.	Iran	Shoot extract	Strongly inhibits cell growth in:	[10, 11, 71, 196]
				- Jurkat tumor cells (200 μ g/ml, >80% inhabitation)	
				- K562 cell line (200 μ g/ml, >50% inhabitation)	
84	<i>Scurrula parasitica</i> L.	Asia	Extract of leaves	Has anti-cancer and inhibitory activity against AML (HL-60 cell line). Flavonoids cease the cell cycle of mutant cells at the G0-G1 phase. Causes apoptosis of cancer cells <i>in vivo</i> by downregulating cyclinD1, Bcl-2, and Ki-67 protein expression and upregulating Bax protein expression.	[102, 197]
85	<i>Scutellaria baicalensis</i> Georgi	China	Baicalin	Baicalin is a selective and potent inhibitor of HTLV-1 replication <i>in vitro</i> , inhibits gag expression in chronically infected T and B cells, induces apoptosis in K562 cells, causes cell cycle cease, and inhibits cell growth by increasing GATA-1 expression and binding in CML.	[92, 198]
			Wogonoside	Wogonoside increases PLSCR1 (phospholipid scramblase 1) transcription, a cell cycle regulator, exerting anti-cancer effects in AML.	
86	<i>Scutellaria orientalis</i> subsp. <i>carica</i> J.R.Edm..	Western Turkey	Baicalein and wogonin	Baicalein has anti-proliferative effects, and wogonin exhibits genotoxic properties.	[199]
87	<i>Simarouba glauca</i> DC.	Asia (Malaysia)	Leaf extracts/petroleum ether	Inhibits the proliferation of K562 cells.	[200]

88	<i>Sophora flavescens</i> Aiton	Asia	Root (Kushen) Sophoranone	Matrine (an alkaloid isolated from Kushen) has anti-tumor activity (reduces leukemia cell survival and cytotoxic effects (induces apoptosis in K562 and U937 human leukemic cell lines).	[201, 202]
89	<i>Sophora tonkinensis</i> Gagnep.	Asia	Roots	Inhibits cell growth and induces apoptosis in the U937 leukemic cell line.	[201]
90	<i>Sophora tonkinensis</i> var. <i>tonkinensis</i> (syn. <i>Sophora subprostrata</i> Chun & H.Y.Chen)	Asia	Roots	Has antioxidant and cytotoxic activity.	[111, 201]
91	<i>Spermacoce articularis</i> L.f.	Tropical Asia	Ursolic acid	Has a cytotoxic effect against HL-60 leukemic cells.	[191]
92	<i>Spermacoce exilis</i> (L.O.Williams) C.D.Adams ex	Malaysia	Ursolic acid	Has a cytotoxic effect against HL-60 leukemic cells.	[191]
93	<i>Spermacoce latifolia</i> Aubl.	Malaysia	Ursolic acid	Has a cytotoxic effect against HL-60 leukemic cells.	[191]
94	<i>Tanacetum parthenium</i> (L.) Sch.Bip.	Central Asia	Parthenolide	Induces apoptosis in AML cells (THP-1 leukemia cells).	[92, 203]
95	<i>Thymus daenensis</i> Čelak.	Iran	Shoot extract	Has strong inhibitory activity against Jurkat tumor cells (200 µg/ml, >80% inhabitation) and the K562 cell line (200 µg/ml, >50% inhabitation).	[11, 71, 204]
96	<i>Thymus vulgaris</i> L.	Asia	Shoot extract	Has strong inhibitory activity against Jurkat tumor cells (200 µg/ml, >80% inhabitation) and the K562 cell line (200 µg/ml, >50% inhabitation).	[11, 71, 90, 100]
97	<i>Tinospora cordifolia</i> (Willd.) Hook.f. & Thomson	India	Diterpenoid lactones	Induces apoptosis in leukemia cells by activating caspase-3 and BAX and inhibiting Bcl-2.	[111, 113, 205]
98	<i>Tithonia diversifolia</i> (Hemsl.) A.Gray	Asia	Sesquiterpenoids	Inhibits the growth of leukemia cells and induces cell differentiation in the HL-60 human promyelocytic leukemia cell line.	[119, 206]
99	<i>Trigonella foenum-graecum</i> L.	Asia	Extract of the seeds	Has anti-proliferative activity. Acts against K562, U937, and L1210 leukemia cell lines. Has cytotoxic effects against CML.	[121, 207, 208]
100	<i>Trigonella foenum-graecum</i> L.	Asia	Extract of dry seeds	Causes membrane disintegration and large vacuole formation in Jurkat cell line.	[208]
101	<i>Ulmus davidiana</i> Planch.	Korea, China, and Japan	Mansonone E	Has an anti-tumor effect on leukemia cell lines HL-60, K562, THP-1, and U937 in a hollow fiber assay.	[89]
102	<i>Vachellia nilotica</i> (L.) P.J.H.Hurter & Mabb. (syn. <i>Acacia nilotica</i> (L.) Willd. ex Delile)	Asia	Apigenin	Induces leukemia cell cycle blockage at the G2/M phase in K562 cells (CML).	[77, 209, 210]
103	<i>Withania somnifera</i> (L.) Dunal	Asia	Withaferin A from roots and leaves	JNK and Akt pathway inhibition and NF-κB suppression result in apoptosis in human leukemic cells. Increases Bax levels via MAPK signaling, inducing a mitochondrial death cascade.	[211–213]
104	<i>Withania somnifera</i> (L.) Dunal	Asia	Crude from the leaves	Has anti-proliferative and proapoptotic effects in different leukemia cell lines.	[214]

Furthermore, it disrupts the reciprocal stimulatory loop between endothelial and leukemic cells by impairing endothelial cell activation [85]. In contrast, xanthochymol's anti-angiogenic effects are linked to its antioxidant properties and modulation of STAT3/VEGF signaling [80].




Fig. 2 *Garcinia indica* in different stages of growth (www.inaturalist.org)

Berberamine (Fig. 3), a bioactive alkaloid derived from *Berberis amurensis* Rupr. (Fig. 4), has shown significant potential in targeting both imatinib-sensitive and -resistant Ph+ CML cells through multiple pro-apoptotic pathways [86]. This compound induces mitochondrial-mediated apoptosis by disrupting the Bcl-2/Bax balance, leading to cytochrome c release and subsequent activation of the caspase cascade. Additionally, berberamine triggers endoplasmic reticulum stress through CHOP activation while simultaneously inhibiting key survival kinases, including BCR-ABL1 and Aurora kinases, making it particularly effective against therapy-resistant CML populations [86].




Fig. 3 2D structure (a) (<https://pubchem.ncbi.nlm.nih.gov/>) and 3D structure (b) of berberamine [88]



Fig. 4 *Berberis amurensis* in different stages of growth (<https://www.inaturalist.org/>) (<https://www.biolib.cz/>)

Complementing these effects, saponins isolated from *Rubus parvifolius* L., a traditional Chinese medicinal herb, demonstrate potent anti-leukemic activity through a distinct but equally compelling mechanism of action [87]. These bioactive compounds activate AMPK-mediated metabolic stress pathways, resulting in mTORC1 inhibition and subsequent suppression of protein synthesis. Concurrent STAT3 pathway inhibition leads to downregulation of critical anti-apoptotic proteins such as Mcl-1 and survivin. The saponins further impair leukemic proliferation by inducing G1/S cell cycle arrest through modulation of cyclin D1/CDK4/6 complexes and upregulation of p21/p27 cyclin-dependent kinase inhibitors [87].

Ulmus davidiana Planch., a tree widely distributed in China, Korea, and Japan, has shown anti-tumor effects against human leukemia cells such as HL-60, K562, and THP-1 cell lines [89]. Another promising function of certain herbs is their inhibitory activity against Jurkat tumor cell lines. *Thymus vulgaris* L., which exhibits such activity, further underscores the potential of medicinal herbs in leukemia treatment [11, 71, 90].

Several medicinal plant species, including *Aglaia leptantha* Miq. and *Combretum afrum* (Eckl. & Zeyh.) Kuntze, have demonstrated their efficacy, particularly in the treatment of CLL. *A. leptantha*, found in Southeast Asia and tropical regions of East Asia, contains silvestrol, that induces the production of total growth inhibition (TGI) and ultimately leads to cell death [68, 91]. *C. afrum*, native to Asia, contains CA4P (combretastatin-A4 prodrug) and has a specific effect on CLL cell lines [92]. CA4P is considered an anti-tubulin/anti-angiogenic agent which induces cell death mainly by mitotic catastrophe [93]. *Moringa oleifera* Lam., also known as drumstick tree, contains quercetin (a flavonoid with antioxidant properties), which inhibits the viability of both AML and ALL cell lines [94, 95]. Additionally, extracts from aerial parts of *Arctium lappa* L. have demonstrated anti-cancer effects on the K562 cell line, further expanding the list of medicinal plants with potential anti-leukemic properties [71]. For a comprehensive list of Asian medicinal plants with potential anti-leukemic properties and insights into their mechanisms of action, refer to Table 1.

CONCLUSION and Future Perspectives

While chemotherapy remains the standard treatment for leukemia, its severe side effects and the growing issue of drug resistance, particularly in cases like CLL, where chromosomal deletions or mutations lead to treatment failure, highlight the urgent need for safer and more effective alternatives. Medicinal plants, with their diverse bioactive compounds, offer a promising solution by targeting leukemia through multiple mechanisms, including apoptosis induction, angiogenesis suppression, selective cytotoxicity, and immune modulation. Promising species such as *Piper betle* (hydroxychavicol, eugenol), *Garcinia indica* (xanthochymol), *Berberis amurensis* (berberamine), and *Moringa oleifera* (quercetin) demonstrate potent anti-leukemic effects, even against drug-resistant cell lines, while minimizing toxicity to healthy cells. Additionally, emerging research on *Artemisia annua* (artemisinin), *Curcuma longa* (curcumin), and *Withania somnifera* (withaferin A) suggests further potential due to their ability to target cancer stem cells and overcome chemoresistance. However, several critical research gaps and unmet clinical needs must be addressed to translate these findings into viable therapies. A major challenge lies in optimizing the bioavailability of plant-derived compounds, as many exhibit poor solubility and absorption that limit their therapeutic potential. Advanced delivery systems such as nanoformulations and lipid-based carriers could help overcome these pharmacokinetic limitations. Another crucial area is the development of effective combination therapies that pair plant bioactives with conventional drugs, such as curcumin with imatinib or artemisinin with venetoclax, to enhance efficacy while reducing the need for chemotherapy doses. Furthermore, the field requires a deeper investigation into subtype-specific mechanisms, particularly for high-risk molecular variants such as TP53-mutated CLL versus BCR-ABL1-positive CML. The identification of predictive biomarkers for treatment responsiveness could enable more personalized approaches to plant-based therapies. Alongside these needs, the requirement for

standardized extraction methods, comprehensive pharmacokinetic studies, and rigorous clinical trials remains essential to validate efficacy and safety in human patients. To fully realize this potential, interdisciplinary collaboration among pharmacologists, oncologists, and traditional medicine experts is essential. The integration of advanced technologies, from AI-driven drug discovery to innovative delivery platforms, could accelerate the development of plant-based anti-leukemic therapies. The shift from conventional chemotherapy to plant-based treatments, supported by rigorous scientific validation, could revolutionize leukemia care, offering more effective, affordable, and patient-friendly solutions. By addressing these unmet needs and bridging current knowledge gaps, medicinal plants may indeed transition from complementary options to first-line adjuvants or alternatives, marking a transformative leap in oncology and emerging as the cornerstone of next-generation leukemia therapies.

Acknowledgement

The authors declare that no external funding or support was received for this study.

Conflict of Interests

The authors have no conflicts of interest.

REFERENCES

- Seyed-Khorrami S-M., Soleimanjahi H., Los M.J., *et al.* Oncolytic viruses as emerging therapy against cancers including Oncovirus-induced cancers. *European Journal of Pharmacology*. 2023; 939: 175393.
- ASCO AS of CO. Understanding Cancer Risk. 2022.
- Brennan P., Davey-Smith G. Identifying novel causes of cancers to enhance cancer prevention: New strategies are needed. *JNCI: Journal of the National Cancer Institute*. 2022; 114: 353–360.
- Wali A.F., Pillai J.R., Talath S., Shivappa P., Sridhar S.B., El-Tanani M., Rangraze I.R., Mohamed O.I., Al Ani N.N. Phytochemicals in breast cancer prevention and treatment: A comprehensive review. *Current Issues in Molecular Biology*. 2025; 47: 30.
- Muthusamy M., Lee S.I. Abiotic stress-induced secondary metabolite production in *Brassica*: opportunities and challenges. *Frontiers in Plant Science*. Epub. 2024. DOI: 10.3389/fpls.2023.1323085.
- Kumar A., P N., Kumar M., Jose A., Tomer V., Oz E., Proestos C., Zeng M., Elobeid T., K S., Oz F. Major phytochemicals: Recent advances in health benefits and extraction method. *Molecules*. 2023; 28: 887.
- Baqer SH., Al-Shawi S.G., Al-Younis Z.K. Quercetin, the potential powerful flavonoid for human and food: A review. *Frontiers in Bioscience-Elite*. Epub. 2024. DOI: 10.31083/j.fbe1603030.
- Dey P., Kundu A., Kumar A., Gupta M., Lee B.M., Bhakta T., Dash S., Kim H.S. Analysis of alkaloids (indole alkaloids, isoquinoline alkaloids, tropane alkaloids). In: *Recent Advances in Natural Products Analysis*. Elsevier. 2020;505–567.
- Tadikamalla N. Implications of chemotherapy, radiation therapy, and surgical treatment in oral cancer. Epub. 2024. DOI: 10.58445/rars.943.
- Hamed A., Bayat M., Asemanni Y., Amirghofran Z. A review of potential anti-cancer properties of some selected medicinal plants grown in Iran. *Journal of Herbal Medicine*. 2022; 33: 100557.
- Esmailbeig M., Kouhpayeh S.A., Amirghofran Z. An investigation of the growth inhibitory capacity of several medicinal plants from Iran on tumor cell lines. *Iranian Journal of Cancer Prevention*. Epub. 2015. DOI: 10.17795/ijcp-4032.
- Ganesh K., Massagué J. Targeting metastatic cancer. *Nature Medicine*. 2021; 27: 34–44.
- Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. 2018; 68: 394–424.
- Belson M., Kingsley B., Holmes A. Risk factors for acute leukemia in children: A review. *Environmental Health Perspectives*. 2007; 115: 138–145.
- Kosik P., Skorvaga M., Belyaev I. Preleukemic fusion genes induced via ionizing radiation. *International Journal of Molecular Sciences*. 2023; 24: 6580.
- Rostami H.A., Rahmanian Z. Laboratory clinical assessment of patients with AML over six years (2010-15) in Hematology-Oncology of Namazi Hospital in Shiraz. *Journal of Fundamental and Applied Sciences*. 2016; 8: 1012.
- Wang H.C., Lin H.L., Shao N., Zhang J.R., Zou J., Ji C.Y. Family history and prior allergies of cancers and the risk of adult leukemia in shandong province, china. *Iranian Journal of Public Health*. 2012; 41: 9–16.
- Cui Y., Yan Y. The global burden of childhood and adolescent leukaemia and attributable risk factors: An analysis of the Global Burden of Disease Study 2019. *Journal of Global Health*. 2024; 14: 04045.
- Rothman N., Smith M.T., Hayes R.B., Traver R.D., Hoener B., Campleman S., Li G.L., Dosemeci M., Linet M., Zhang L., Xi L., Wacholder S., Lu W., Meyer K.B., Titenko-Holland N., Stewart J.T., Yin S., Ross D. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C->T mutation and rapid fractional excretion of chlorzoxazone. *Cancer Research*. 1997; 57: 2839–42.
- Ekpa Q.L., Akahara P.C., Anderson A.M., Adekoya O.O., Ajayi O.O., Alabi P.O., Okobi O.E., Jaiyeola O., Ekanem M.S. A review of acute lymphocytic leukemia (ALL) in the pediatric population: Evaluating current trends and changes in guidelines in the past decade. *Cureus*. Epub. 2023. DOI: 10.7759/cureus.49930.
- Blanco-Lopez J., Iguacel I., Pisanu S., Almeida C., Steliarova-Foucher E., Sierens C., Gunter M., Ladas E., Barr R., Van Herck K., Huybrechts I. Role of maternal diet in the risk of childhood acute leukemia: A systematic review and meta-analysis. *International Journal of Environmental Research and Public Health*. 2023; 20: 5428.
- Fithriyah I., Konginan A., Maramis M., Mahajudin M., Muhdi N., Margono H., Warsiki E., Basoeki L., Yitnamurti S. The epidemiology of pediatric cancer in the palliative care unit at Dr. Soetomo general hospital, Surabaya. *Jurnal Berkala Epidemiologi*. 2020; 8: 65.
- Chen P., Liu X., Zhao Y., Hu Y., Guo J., Wang H. Global, national, and regional burden of acute myeloid leukemia among 60–89 years-old individuals: insights from a study covering the period 1990 to 2019. *Frontiers in Public Health*.; 11. Epub ahead of print 11 January 2024. DOI: 10.3389/fpubh.2023.1329529.
- Balasubramaniam G., Saoba S.L., Sarhade M.N., Kolekar S.A. Lifestyle factors including diet and leukemia development: a case-control study from Mumbai, India. *Asian Pacific Journal of Cancer Prevention*. 2013; 14: 5657–5661.
- Ma X., Park Y., Mayne S.T., Wang R., Sinha R., Hollenbeck A.R., Schatzkin A., Cross A.J. Diet, lifestyle, and acute myeloid leukemia in the NIH-AARP Cohort. *American Journal of Epidemiology*. 2010; 171: 312–322.
- Thair Tahir N., Thamer N.A., Mahmood N.A. Role of Vitamin D in the diagnosis of acute Myeloid Leukemia. *Bionatura*. 2023; 8: 1–5.
- Kasteng F., Sobocki P., Svedman C., Lundkvist J. Economic evaluations of leukemia: A review of the literature. *International Journal of Technology Assessment in Health Care*. 2007; 23: 43–53.
- Au W.Y., Caguioa P.B., Chuah C., Hsu S.C., Jootar S., Kim D-W., Kweon I-Y., O'Neil W.M., Saikia T.K., Wang J. Chronic myeloid leukemia in Asia. *International Journal of Hematology*. 2009; 89: 14–23.
- Yang S-M., Li J-Y., Gale P., Huang X-J. The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology? *Blood Reviews*. 2015; 29: 205–213.
- Daskalakis M., Feller A., Noetzli J., Bonadies N., Arndt V., Baerlocher G.M. Potential to improve therapy of Chronic Myeloid Leukemia (CML), especially for patients with older age: Incidence, mortality, and survival rates of patients with CML in Switzerland from 1995 to 2017. *Cancers*. 2021; 13: 6269.

31. Park S., Bae J., Nam B-H., Yoo K-Y. Aetiology of cancer in Asia. *Asian Pacific Journal of Cancer Prevention*. 2008; 9: 371–380.
32. Saedi TA., Md Noor S., Ismail P., Othman F. The effects of herbs and fruits on leukaemia. *Evidence-Based Complementary and Alternative Medicine*. Epub. 2014. DOI: 10.1155/2014/494136.
33. Kuang S-Q., Tong W-G., Yang H., Lin W., Lee M.K., Fang ZH., Wei Y., Jelinek J., Issa J-P., Garcia-Manero G. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. *Leukemia*. 2008; 22: 1529–1538.
34. Wilson F., Tefferi A. Acute lymphocytic leukemia with eosinophilia: Two case reports and a literature review. *Leukemia & Lymphoma*. 2005; 46: 1045–1050.
35. Thiel E., Kranz B., Raghavachar A., Bartram C., Löffler H., Messerer D., Ganser A., Ludwig W., Buchner T., Hoelzer D. Prethymic phenotype and genotype of pre-T (CD7+/ER-) cell leukemia and its clinical significance within adult acute lymphoblastic leukemia [see comments]. *Blood*. 1989; 73: 1247–1258.
36. Chiaretti S., Li X., Gentleman R., Vitale A., Vignetti M., Mandelli F., Ritz J., Foa R. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. *Blood*. 2004; 103: 2771–2778.
37. Ames B.N. Cancer prevention and diet: Help from single nucleotide polymorphisms. *Proceedings of the National Academy of Sciences*. 1999; 96: 12216–12218.
38. Larson R.A. Managing CNS disease in adults with acute lymphoblastic leukemia. *Leukemia & Lymphoma*. 2018; 59: 3–13.
39. Lenk L., Alsadeq A., Schewe D.M. Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data. *Cancer and Metastasis Reviews*. 2020; 39: 173–187.
40. Ikonomidou C. Cerebrospinal fluid biomarkers in childhood leukemias. *Cancers*. 2021; 13: 438.
41. Tang X., Mai H., Wang L., Chen S., Chen F., Li T., Liu Y., Zhou G., Liu S., Wang Y., Liu S., Fu X., Wen F. Diagnostic significance of cerebrospinal fluid flow cytometry in Chinese children with B lineage acute lymphoblastic leukemia. *BMC Pediatrics*. 2024; 24: 204.
42. Deak D., Gorcea-Andronic N., Sas V., Teodorescu P., Constantinescu C., Iluta S., Pasca S., Hotea I., Turcas C., Moisoiu V., Zimta A-A., Galdean S., Steinheber J., Rus I., Rauch S., Richlitzki C., Munteanu R., Jurj A., Petrushev B. *et al.* A narrative review of central nervous system involvement in acute leukemias. *Annals of Translational Medicine*. 2021; 9: 68–68.
43. Rodgers AH. Principles of neuropharmacodynamics: As applied to neuro-oncology. In: *Brain and Spinal Tumors - Primary and Secondary*. IntechOpen. Epub. 2020. DOI: 10.5772/intechopen.82653.
44. Del Principe MI., Maurillo L., Buccisano F., Sconocchia G., Cefalo M., De Santis G., Di Veroli A., Ditto C., Nasso D., Postorino M., Refrigieri M., Attrotto C., Del Poeta G., Amadori S., Venditti A. Central nervous system involvement in adult acute lymphoblastic leukemia: Diagnostic tools, prophylaxis and therapy. *Mediterranean Journal of Hematology and Infectious Diseases*. 2014; 6: e2014075.
45. Wu S.Y., Short N.J., Nasr L., Dabaja B.S., Fang P.Q. Central nervous system prophylaxis and treatment in acute leukemias. *Current Treatment Options in Oncology*. 2022; 23: 1829–1844.
46. Xue L., Shang Q., Lu A., Zuo Y., Ding M., Zhang L., Jia Y. Diagnostic value and prognosis significance of cerebrospinal fluid examination by flow cytometry in pediatric acute lymphoblastic leukemia. *Technology in Cancer Research & Treatment*; 22. Epub ahead of print 22 January 2023. DOI: 10.1177/15330338231181025.
47. Bürger B., Zimmermann M., Mann G., Kühl J., Löning L., Riehm H., Reiter A., Schrappe M. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture. *Journal of Clinical Oncology*. 2003; 21: 184–188.
48. Tawil M., Bekdash A., Mroueh M., Daher C.F., Abi-Habib R.J. Wild carrot oil extract is selectively cytotoxic to human acute myeloid leukemia cells. *Asian Pacific Journal of Cancer Prevention*. 2015; 16: 761–767.
49. Rubnitz J.E., Gibson B., Smith F.O. Acute myeloid leukemia. *Pediatric Clinics of North America*. 2008; 55: 21–51.
50. Albrecht T.A. Physiologic and psychological symptoms experienced by adults with acute leukemia: An integrative literature review. *Oncology Nursing Forum*. 2014; 41: 286–295.
51. Döhner H., Weisdorf DJ., Bloomfield CD. Acute myeloid leukemia. *New England Journal of Medicine*. 2015; 373: 1136–1152.
52. Calgarotto A.K., Maso V., Junior G.C.F., Nowill A.E., Filho P.L., Vassallo J., Saad S.T.O. Antitumor activities of Quercetin and Green Tea in xenografts of human leukemia HL60 cells. *Scientific Reports*. 2018; 8: 3459.
53. Crossnohere N.L., Richardson D.R., Reinhart C., O'Donoghue B., Love S.M., Smith B.D., Bridges J.F.P. Side effects from acute myeloid leukemia treatment: results from a national survey. *Current Medical Research and Opinion*. 2019; 35: 1965–1970.
54. Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., Pendergast A.M., Bronson R., Aster J.C., Scott M.L., Baltimore D. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. *Blood*. 1998; 92: 3780–3792.
55. Rehman S., Choe K., Yoo H. Review on a traditional herbal medicine, *Eurycoma longifolia* Jack (Tongkat Ali): Its traditional uses, chemistry, evidence-based pharmacology and toxicology. *Molecules*. 2016; 21: 331.
56. Lambert G.K., Duhme-Klair A-K., Morgan T., Ramjee M.K. The background, discovery and clinical development of BCR-ABL inhibitors. *Drug Discovery Today*. 2013; 18: 992–1000.
57. Bandyopadhyay G., Biswas T., Roy K.C., Mandal S., Mandal C., Pal B.C., Bhattacharya S., Rakshit S., Bhattacharya DK., Chaudhuri U., Konar A., Bandyopadhyay S. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. *Blood*. 2004; 104: 2514–2522.
58. Mian A.A., Metodieva A., Najajreh Y., Ottmann O.G., Mahajna J., Ruthardt M. p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. *Haematologica*. 2012; 97: 251–257.
59. Rafiei A., Mian A.A., Döring C., Metodieva A., Oancea C., Thalheimer F.B., Hansmann M.L., Ottmann OG., Ruthardt M. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-positive acute lymphatic leukemia. *PLOS Genetics*. 2015; 11: e1005144.
60. Roskoski R. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia. *Pharmacological Research*. 2022; 178: 106156.
61. Cortes J., Kantarjian H. How I treat newly diagnosed chronic phase CML. *Blood*. 2012; 120: 1390–1397.
62. Holyoake T., Jiang X., Drummond M., Eaves A., Eaves C. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. *Leukemia*. 2002; 16: 549–558.
63. Ruchlemer R., Polliack A. Geography, ethnicity and “roots” in chronic lymphocytic leukemia. *Leukemia & Lymphoma*. 2013; 54: 1142–1150.
64. Hallek M., Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. *American Journal of Hematology*. 2021; 96: 1679–1705.
65. Morrison E.J., Flynn J.M., Jones J., Byrd J.C., Andersen B.L. Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia. *Annals of Hematology*. 2016; 95: 1989–1997.
66. Döhner H., Stilgenbauer S., Benner A., Leupolt E., Kröber A., Bullinger L., Döhner K., Bentz M., Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. *New England Journal of Medicine*. 2000; 343: 1910–1916.
67. Grever M.R., Lucas D.M., Dewald G.W., Neuberger D.S., Reed J.C., Kitada S., Flinn I.W., Tallman M.S., Appelbaum F.R., Larson R.A., Paietta E., Jelinek D.F., Gribben J.G., Byrd J.C. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US

- intergroup phase III trial E2997. *Journal of Clinical Oncology*. 2007; 25: 799–804.
68. Lucas D.M., Edwards R.B., Lozanski G., West D.A., Shin J.D., Vargo M.A., Davis M.E., Rozewski D.M., Johnson A.J., Su B-N., Goettl V.M., Heerema N.A., Lin T.S., Lehman A., Zhang X., Jarjoura D., Newman D.J., Byrd J.C., Kinghorn A.D. *et al.* The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. *Blood*. 2009; 113: 4656–4666.
 69. Yang S., Varghese A.M., Sood N., Chiattonne C., Akinola N.O., Huang X., Gale R.P. Ethnic and geographic diversity of chronic lymphocytic leukaemia. *Leukemia*. 2021; 35: 433–439.
 70. Shakil SSM., Gowan M., Hughes K., Azam M.N.K., Ahmed M.N. A narrative review of the ethnomedicinal usage of *Cannabis sativa* Linnaeus as traditional phytomedicine by folk medicine practitioners of Bangladesh. *Journal of Cannabis Research*. 2021; 3: 8.
 71. Buso P., Manfredini S., Reza Ahmadi-Ashtiani H., Sciabica S., Buzzi R., Vertuani S., Baldisserotto A. Iranian medicinal plants: From ethnomedicine to actual studies. *Medicina*. 2020; 56: 97.
 72. Rather L.J., Shahid-ul-Islam., Mohammad F. *Acacia nilotica* (L.): A review of its traditional uses, phytochemistry, and pharmacology. *Sustainable Chemistry and Pharmacy*. 2015; 2: 12–30.
 73. Roustaei B., Zarezadeh S., Ghotbi-Ravandi A.A. A review on epilepsy, current treatments, and potential of medicinal plants as an alternative treatment. *Neurological Sciences*. 2023; 44: 4291–4306.
 74. Alipour Z., Zarezadeh S., Ghotbi-Ravandi AA. The potential of anti-coronavirus plant secondary metabolites in COVID-19 drug discovery as an alternative to repurposed drugs: A review. *Planta Medica*. 2024; 90: 172–203.
 75. Cao J., Zhao X., Ma Y., Yang J., Li F. Total saponins from *Rubus parvifolius* L. inhibits cell proliferation, migration and invasion of malignant melanoma in vitro and in vivo. *Bioscience Reports*; 41. Epub ahead of print 29 January 2021. DOI: 10.1042/BSR20201178.
 76. Kim C., Song H-S., Park H., Kim B. Activation of ER stress-dependent miR-216b has a critical role in *Salvia miltiorrhiza* ethanol-extract-induced apoptosis in U266 and U937 cells. *International Journal of Molecular Sciences*. 2018; 19: 1240.
 77. Sakthive K.M., Kannan N., Angeline A., Guruvayoorappan C. Anticancer activity of *Acacia nilotica* (L.) Wild. Ex. Delile subsp. *indica* against Dalton's Ascitic Lymphoma induced solid and ascitic tumor model. *Asian Pacific Journal of Cancer Prevention*. 2012; 13: 3989–3995.
 78. Cochrane C.B., Nair P.R., Melnick S.J., Resek A.P., Ramachandran C. Anticancer effects of *Annona glabra* plant extracts against human leukemia cell lines. *Anticancer Research*. 2008; 28: 965–971.
 79. Spagnuolo C., Russo M., Bilotto S., Tedesco I., Laratta B., Russo G.L. Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia. *Annals of the New York Academy of Sciences*. 2012; 1259: 95–103.
 80. Padhye S., Ahmad A., Oswal N., Sarkar F.H. Emerging role of Garcinol, the antioxidant chalcone from *Garcinia indica* Choisy and its synthetic analogs. *Journal of Hematology & Oncology*. 2009; 2: 38.
 81. Musika S., Indrapichate K. Cytotoxicity and apoptosis induction of Mintweed (*Hyptis suaveolens* L. Poit) leaf extracts on human T-leukemia cell line, Jurkat cells. *World Journal of Pharmacy and Pharmaceutical Sciences*. 2014; 3: 304–317.
 82. Fazal F., Mane P.P., Rai M.P., Thilakchand K.R., Bhat H.P., Kamble P.S., Palatty P.L., Baliga M.S. The phytochemistry, traditional uses and pharmacology of Piper Betel. linn (Betel Leaf): A pan-asiatic medicinal plant. *Chinese Journal of Integrative Medicine*. Epub. 2014. DOI: 10.1007/s11655-013-1334-1.
 83. Morton J.F. Widespread tannin intake via stimulants and masticatories, especially Guaraná, Kola nut, betel vine, and accessories. In: *Plant Polyphenols*. 1992;739–765.
 84. Kanjwani D.G., Marathe T.P., Chiplunkar S.V., Sathaye S.S. Evaluation of immunomodulatory activity of methanolic extract of Piper betel. *Scandinavian Journal of Immunology*. 2008; 67: 589–593.
 85. Dell'Eva R., Ambrosini C., Vannini N., Piaggio G., Albini A., Ferrari N. AKT/NF- κ B inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. *Cancer*. 2007; 110: 2007–2011.
 86. Kainsa S., Kumar P., Rani P. Medicinal plants of Asian origin having anticancer potential: short review. *Asian Journal of Biomedical and Pharmaceutical Sciences*. 2012; 2: 1–11.
 87. Ge Y-Q., Xu X-F., Yang B., Chen Z., Cheng R-B. Saponins from *Rubus parvifolius* L. induce apoptosis in human chronic myeloid leukemia cells through AMPK activation and STAT3 inhibition. *Asian Pacific Journal of Cancer Prevention*. 2014; 15: 5455–5461.
 88. Dong L., Xie H., Jia L., Hong L., Li G. Inhibition of amyloid β aggregation and cytotoxicity by berbamine hydrochloride. *Chemistry – A European Journal*. Epub. 2023. DOI: 10.1002/chem.202301865.
 89. Lee KH., Cho CH., Rhee KH. Anti-leukemic and topoisomerase I inhibitory effect of Mansonone E isolated from *Ulmus davidiana*. *Journal of Medicinal Plants Research*. 2012; 6: 4091–4095.
 90. Asadi-Samani M., Rafieian-Kopaei M., Lorigooini Z., Shirzad H. A screening of growth inhibitory activity of Iranian medicinal plants on prostate cancer cell lines. *BioMedicine*. 2018; 8: 8.
 91. Kinghorn A.D., Pan L., Fletcher J.N., Chai H. The relevance of higher plants in lead compound discovery programs. *Journal of Natural Products*. 2011; 74: 1539–1555.
 92. Izuqbuna O. Leukemia chemoprevention and therapeutic potentials: Selected medicinal plants with anti-leukemic activities. *Nutrition and Cancer*. 2022; 74: 437–449.
 93. Nabha S.M., Mohammad R.M., Dandashi M.H., Coupaye-Gerard B., Aboukameel A., Pettit G.R., Al-Katib A.M. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly (ADP-ribose) polymerase cleavage. *Clinical Cancer Research*. 2002; 8: 2735–2741.
 94. Khalafalla M.M., Abdellatef E., Dafalla H.M., Nassrallah A.A., Aboul-Enein K.M., Lightfoot D.A., El-Deeb F.E., El-Shemy H.A. Active principle from *Moringa oleifera* Lam leaves effective against two leukemias and a hepatocarcinoma. *African Journal of Biotechnology*. 2011; 9: 8467–8471.
 95. Rudani M., Chhotala Y., Prajapati R., Sailor G., Jain V. *Alstonia scholaris*: A potent Asian medicinal plant (a comprehensive phytopharmacological review). *Pharma Science Monitor*. 2020; 11: 19–39.
 96. Wong S., Lim Y., Abdullah N., Nordin F. Antiproliferative and phytochemical analyses of leaf extracts of ten Apocynaceae species. *Pharmacognosy Research*. 2011; 3: 100.
 97. Bagheri G., Mirzaei M., Mehrabi R., Sharifi-Rad J. Cytotoxic and antioxidant activities of *Alstonia scholaris*, *Alstonia venenata* and *Moringa oleifera* plants from India. *Jundishapur Journal of Natural Pharmaceutical Products*. Epub. 2016. DOI: 10.17795/jjnpp-31129.
 98. Wang C-M., Chen H-T., Wu Z-Y., Jhan Y-L., Shyu C-L., Chou C-H. Antibacterial and synergistic activity of pentacyclic triterpenoids isolated from *Alstonia scholaris*. *Molecules*. 2016; 21: 139.
 99. Rahman M.M., Khan M.A. Anti-cancer potential of South Asian plants. *Natural Products and Bioprospecting*. 2013; 3: 74–88.
 100. Adham A.N., Hegazy M.E.F., Naqishbandi A.M., Efferth T. Induction of apoptosis, autophagy and ferroptosis by *Thymus vulgaris* and *Arctium lappa* extract in leukemia and multiple myeloma cell lines. *Molecules*. 2020; 25: 5016.
 101. Gurunanselage Don R.A.S., Yap M.K.K. *Arctium lappa* L. Root extract induces cell death via mitochondrial-mediated caspase-dependent apoptosis in Jurkat human leukemic T cells. *Biomedicine & Pharmacotherapy*. 2019; 110: 918–929.
 102. Khan T., Ali M., Khan A., Nisar P., Jan SA., Afridi S., Shinwari ZK. Anticancer plants: A review of the active phytochemicals, applications in animal models, and regulatory aspects. *Biomolecules*. 2019; 10: 47.
 103. Kumar B., Kalvala A., Chu S., Rosen S., Forman SJ., Marcucci G., Chen C-C., Pullarkat V. Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. *Leukemia Research*. 2017; 59: 124–135.
 104. Lai H., Singh N.P. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. *Cancer Letters*. 2006; 231: 43–48.

105. Rasooli I., Rezaee M.B., Moosavi M.L., Jaimand K. Microbial sensitivity to and chemical properties of the essential oil of *Artemisia annua* L. *Journal of Essential Oil Research*. 2003; 15: 59–62.
106. Lee T.K., Vairappan C.S. Antioxidant, antibacterial and cytotoxic activities of essential oils and ethanol extracts of selected South East Asian herbs. *Journal of Medicinal Plants Research*. 2011; 5: 5284–5290.
107. Song X., Wen X., He J., Zhao H., Li S., Wang M. Phytochemical components and biological activities of *Artemisia argyi*. *Journal of Functional Foods*. 2019; 52: 648–662.
108. Huang L.H., Yan Q.J., Kopparapu N.K., Jiang Z.Q., Sun Y. *Astragalus membranaceus* lectin (AML) induces caspase-dependent apoptosis in human leukemia cells. *Cell Proliferation*. 2012; 45: 15–21.
109. Shahrajabian M.H., Sun W., Cheng Q. A short review of Goji berry, Ginger, Ginseng and *Astragalus* in traditional Chinese and Asian medicine. *Black Sea Journal of Health Science*. 2020; 3: 36–45.
110. Sheng Z., Jiang Y., Liu J., Yang B. UHPLC–MS/MS analysis on flavonoids composition in *Astragalus membranaceus* and their antioxidant activity. *Antioxidants*. 2021; 10: 1852.
111. Ahmeda A., Zangeneh A., Zangeneh M.M. Green synthesis and chemical characterization of gold nanoparticle synthesized using *Camellia sinensis* leaf aqueous extract for the treatment of acute myeloid leukemia in comparison to daunorubicin in a leukemic mouse model. *Appl Organomet Chem.*; 34. Epub ahead of print 2020. DOI: 10.1002/aoc.5290.
112. Singh R., Nawale L., Arkile M., Wadhvani S., Shedbalkar U., Chopade S., Sarkar D., Chopade B.A. Phytogenic silver, gold, and bimetallic nanoparticles as novel antitubercular agents. *International Journal of Nanomedicine*. 2016; 1889.
113. Soni A., Krishnamurthy R. Plants-the next generation treatment of leukemia. *Indian Journal of Plant Sciences*. 2013; 2: 117–125.
114. Talukdar S., Rahman M., Paul S. A review on *Barleria prionitis*: Its pharmacognosy, phytochemicals and traditional use. *Journal of Advances in Medical and Pharmaceutical Sciences*. 2015; 4: 1–13.
115. Bartolome A.P., Villaseñor I.M., Yang W.-C. *Bidens pilosa* L. (Asteraceae): Botanical properties, traditional uses, phytochemistry, and pharmacology. *Evidence-Based Complementary and Alternative Medicine*. 2013; 2013: 1–51.
116. Chang J.-S., Chiang L.-C., Chen C.-C., Liu L.-T., Wang K.-C., Lin C.-C. Antileukemic activity of *Bidens pilosa* L. var. minor (Blume) Sherff and *Houttuynia cordata* Thunb. *The American Journal of Chinese Medicine*. 2001; 29: 303–312.
117. Hasegawa H., Yamada Y., Komiyama K., Hayashi M., Ishibashi M., Yoshida T., Sakai T., Koyano T., Kam T.-S., Murata K., Sugahara K., Tsuruda K., Akamatsu N., Tsukasaki K., Masuda M., Takasu N., Kamihira S. Dihydroflavonol BB-1, an extract of natural plant *Blumea balsamifera*, abrogates TRAIL resistance in leukemia cells. *Blood*. 2006; 107: 679–688.
118. Norikura T., Kojima-Yuasa A., Shimizu M., Huang X., Xu S., Kametani S., Rho S.-N., Kennedy D.O., Matsui-Yuasa I. Anticancer activities and mechanisms of *Blumea balsamifera* extract in hepatocellular carcinoma cells. *The American Journal of Chinese Medicine*. 2008; 36: 411–424.
119. Chiang L.-C., Cheng H.-Y., Chen C.-C., Lin C.-C. In vitro anti-leukemic and antiviral activities of traditionally used medicinal plants in Taiwan. *The American Journal of Chinese Medicine*. 2004; 32: 695–704.
120. Al-Saidi S., Rameshkumar K.B., Hisham A., Sivakumar N., Al-Kindy S. Composition and antibacterial activity of the essential oils of four commercial grades of Omani Luban, the oleo-gum resin of *Boswellia sacra* Flueck. *Chemistry & Biodiversity*. 2012; 9: 615–624.
121. Abdul-Jalil Farhan A., Gull M., Abdulaziz Rahimuddin S., Abdullah Kumosani T., Mahmoud Al-Hejin A., Kausar A., Aamer Mehmood M. Antimicrobial activity and biochemical profiling of selected medicinal plants against blood cancer clinical isolates. *Biosciences, Biotechnology Research Asia*. 2017; 14: 1277–1284.
122. Poeckel D., Werz O. Boswellic acids: Biological actions and molecular targets. *Current Medicinal Chemistry*. 2006; 13: 3359–3369.
123. Alraddadi B.G., Shin H.-J. Biochemical properties and cosmetic uses of *Commiphora myrrha* and *Boswellia serrata*. *Cosmetics*. 2022; 9: 119.
124. Bhushan S., Kumar A., Malik F., Andotra S.S., Sethi V.K., Kaur I.P., Taneja S.C., Qazi G.N., Singh J. A triterpenediol from *Boswellia serrata* induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells. *Apoptosis*. 2007; 12: 1911–1926.
125. Cucu A.-A., Bacu G.-M., Cucu A.-B., Dezsi Ş., Lujerdean C., Hegeduş IC., Bobiş O., Moise A.R., Dezmirean D.S. *Calluna vulgaris* as a valuable source of bioactive compounds: Exploring Its phytochemical profile, biological activities and apitherapeutic potential. *Plants*. 2022; 11: 1993.
126. Liu J. Pharmacology of oleanolic acid and ursolic acid. *Journal of Ethnopharmacology*. 1995; 49: 57–68.
127. Simon A., Najid A., Chulia A.J., Delage C., Rigaud M. Inhibition of lipoxygenase activity and HL60 leukemic cell proliferation by ursolic acid isolated from heather flowers (*Calluna vulgaris*). *Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism*. 1992; 1125: 68–72.
128. Juncker T., Schumacher M., Dicato M., Diederich M. UNBS1450 from *Calotropis procera* as a regulator of signaling pathways involved in proliferation and cell death. *Biochemical Pharmacology*. 2009; 78: 1–10.
129. Chang Y., Zheng C., Chinnathambi A., Alahmadi T.A., Alharbi S.A. Cytotoxicity, anti-acute leukemia, and antioxidant properties of gold nanoparticles green-synthesized using *Cannabis sativa* L leaf aqueous extract. *Arabian Journal of Chemistry*. 2021; 14: 103060.
130. Isidore E., Karim H., Ioannou I. Extraction of phenolic compounds and terpenes from *Cannabis sativa* L. by-products: From conventional to intensified processes. *Antioxidants*. 2021; 10: 942.
131. Patel J., Choubisa B. Plant derived compounds having activity against P388 and L1210 leukemia cells. *Chemical Sciences Journal.*; 2. Epub ahead of print 2011. DOI: 10.4172/2150-3494.1000024.
132. Tiong S., Looi C., Hazni H., Arya A., Paydar M., Wong W., Cheah S.-C., Mustafa M., Awang K. Antidiabetic and antioxidant properties of alkaloids from *Catharanthus roseus* (L.) G. Don. *Molecules*. 2013; 18: 9770–9784.
133. Politi M., Braca A., De Tommasi N., Morelli I., Manunta A., Battinelli L., Mazzanti G. Antimicrobial diterpenes from the seeds of *Cephalotaxus harringtonia* var. *drupacea*. *Planta Medica*. 2003; 69: 468–470.
134. Anuchapreeda S., Chueahongthong F., Viriyaadhammaa N., Panyajai P., Anzawa R., Tima S., Ampasavate C., Saiai A., Rungrojsakul M., Usuki T., Okonogi S. Antileukemic cell proliferation of active compounds from kaffir lime (*Citrus hystrix*) leaves. *Molecules*. 2020; 25: 1300.
135. Chueahongthong F., Ampasavate C., Okonogi S., Tima S., Anuchapreeda S. Cytotoxic effects of crude kaffir lime (*Citrus hystrix*, DC.) leaf fractional extracts on leukemic cell lines. *Journal of Medicinal Plants Research*. 2011; 5: 3097–3105.
136. Siew Y.-Y., Yew H.-C., Neo S.-Y., Seow S.-V., Lew S.-M., Lim S.-W., Lim C.S.E.-S., Ng Y.-C., Seetoh W.-G., Ali A., Tan C.-H., Koh H.-L. Evaluation of anti-proliferative activity of medicinal plants used in Asian Traditional Medicine to treat cancer. *Journal of Ethnopharmacology*. 2019; 235: 75–87.
137. Potikanond S., Chiranthanot N., Khonsung P., Teekachunhatean S. Cytotoxic effect of *Cosciniium fenestratum* on human head and neck cancer cell line (HN31). *Evidence-Based Complementary and Alternative Medicine*. 2015; 2015: 1–8.
138. Xavier T.F., Kannan M., Lija L., Auxillia A., Rose A.K.F., Kumar S.S. Ethnobotanical study of Kani tribes in Thoduhills of Kerala, South India. *Journal of Ethnopharmacology*. 2014; 152: 78–90.
139. Reuter S., Charlet J., Juncker T., Teiten M., Dicato M., Diederich M. Effect of curcumin on nuclear factor κB signaling pathways in human chronic myelogenous K562 leukemia cells. *Annals of the New York Academy of Sciences*. 2009; 1171: 436–447.
140. Khalil N., Ashour M., Singab A.N., Salama O. Bioassay guided fractionation and cytotoxic activity of *Daucus carota* var. *boissieri*. *Future Journal of Pharmaceutical Sciences*. 2018; 4: 14–17.
141. Moghaddam G., Ebrahimi S.A., Rahbar-Roshandel N., Foroumadi A. Antiproliferative activity of flavonoids: Influence of the sequential methoxylation state of the flavonoid structure. *Phytotherapy Research*. 2012; 26: 1023–1028.

142. Otroshy M., Moradi K. Micropropagation of medicinal plant *dracocephalum kotschy boiss.* via nodal cutting technique. *Journal of Medicinal Plants Research.* 2011; 5: 5967–5972.
143. Talari M., Seydi E., Salimi A., Mohsenifar Z., Kamalinejad M., Pourahmad J. *Dracocephalum*: Novel anticancer plant acting on liver cancer cell mitochondria. *BioMed Research International.* 2014; 2014: 1–10.
144. Sobhani A.M., Ebrahimi S-A., Mahmoudian M. An in vitro evaluation of human DNA topoisomerase I inhibition by *Peganum harmala* L. seeds extract and its beta-carboline alkaloids. *Journal of Pharmacy & Pharmaceutical Sciences.* 2002; 5: 19–23.
145. Adamczyk K., Olech M., Abramek J., Pietrzak W., Kuźniewski R., Bogucka-Kocka A., Nowak R., Ptaszyńska A.A., Rapacka-Gackowska A., Skalski T., Strzemiński M., Sowa I., Wójciak-Kosior M., Feldo M., Załuski D. *Eleutherococcus* species cultivated in Europe: A new source of compounds with antiacetylcholinesterase, antihyaluronidase, anti-DPPH, and cytotoxic activities. *Oxidative Medicine and Cellular Longevity.* 2019; 2019: 1–10.
146. Załuski D., Smolarz H.D., Bogucka-Kocka A. Cytotoxic activity of ethanolic extracts of *Eleutherococcus* species cultivated in Poland on HL60 leukemia cell line. *Current Issues in Pharmacy and Medical Sciences.* 2014; 27: 41–45.
147. Jusoh S.A.M., Seeni A., Johan M.F. Antiproliferative and pro-apoptotic effect of *P. sacharosa*, *E. elatior* and *P. granatum* aqueous extract on human myeloid leukaemia: A preliminary study. *Asian Journal of Medical Research.* 2016; 5: 5–10.
148. Krajarng A., Chulasiri M., Watanapokasin R. *Etingera elatior* extract promotes cell death in B16 melanoma cells via down-regulation of ERK and Akt signaling pathways. *BMC Complementary and Alternative Medicine.* 2017; 17: 415.
149. Sharma N., Samarakoon K., Gyawali R., Park Y-H., Lee S-J., Oh S., Lee T-H., Jeong D. Evaluation of the antioxidant, anti-inflammatory, and anticancer activities of *Euphorbia hirta* ethanolic extract. *Molecules.* 2014; 19: 14567–14581.
150. Steinmann D., Ganzera M. Recent advances on HPLC/MS in medicinal plant analysis. *Journal of Pharmaceutical and Biomedical Analysis.* 2011; 55: 744–757.
151. Zhang L., Shu X., Ding A., Yu L., Tang Y., Duan J., Shang E., Shen X. LC–DAD–ESI–MS–MS separation and chemical characterization of the inflammatory fraction of the roots of *Euphorbia kansui*. *Chromatographia.* 2009; 70: 805–810.
152. Kumar D., Sharma P., Singh H., Nepali K., Gupta G.K., Jain S.K., Ntie-Kang F. The value of pyrans as anticancer scaffolds in medicinal chemistry. *RSC Advances.* 2017; 7: 36977–36999.
153. Matsumoto K., Akao Y., Kobayashi E., Ohguchi K., Ito T., Tanaka T., Inuma M., Nozawa Y. Induction of apoptosis by xanthones from mangosteen in human leukemia cell lines. *Journal of Natural Products.* 2003; 66: 1124–1127.
154. Lewin G., Shridhar N.B., Aubert G., Thoret S., Dubois J., Cresteil T. Synthesis of antiproliferative flavones from calycopterin, major flavonoid of *Calycopteris floribunda* Lamk. *Bioorganic & Medicinal Chemistry.* 2011; 19: 186–196.
155. Ahmad A., Hayat I., Arif S., Masud T., Khalid N., Ahmed A. Mechanisms involved in the therapeutic effects of soybean (*Glycine Max*). *International Journal of Food Properties.* 2014; 17: 1332–1354.
156. Andres S., Abraham K., Appel K.E., Lampen A. Risks and benefits of dietary isoflavones for cancer. *Critical Reviews in Toxicology.* 2011; 41: 463–506.
157. Badole S.L., Bodhankar S.L. *Glycine max* (soybean) treatment for diabetes. In: *Bioactive Food as Dietary Interventions for Diabetes.* Elsevier. 2013; 77–82.
158. Liu J., Wen X., Kan J., Jin C. Structural characterization of two water-soluble polysaccharides from black soybean (*Glycine max* (L.) Merr.). *Journal of Agricultural and Food Chemistry.* 2015; 63: 225–234.
159. Yeap S.K., Ho W.Y., Beh B.K., Liang W.S., Ky H., Youns A.H.N., Alitheen N.B. *Vernonia amygdalina*, an ethnoveterinary and ethnomedical used green vegetable with multiple bioactivities. *Journal of Medicinal Plants Research.* 2010; 4: 2787–2812.
160. Kujoana T.C., Weeks W.J., Van der Westhuizen M.M., Mabelebele M., Sebola N.A. Potential significance of kenaf (*Hibiscus cannabinus* L.) to global food and feed industries. *Cogent Food & Agriculture.* Epub. 2023. DOI: 10.1080/23311932.2023.2184014.
161. Tima S., Phanphuech B., Anuchapreeda S. Cytotoxicity study of *Houttuynia cordata* Thunb crude extracts on HL-60 and Molt4 leukemic cell line. *Bulletin of Chiang Mai Associated Medical Sciences.* 2010; 43: 1–30.
162. Shih K., Huang W., Chang C., Feng C. Effects of *Ixeris Chinensis* (Thunb.) Nakai boiling water extract on hepatitis B viral activity and hepatocellular carcinoma. *African Journal of Traditional, Complementary and Alternative Medicines.* Epub. 2013. DOI: 10.4314/ajtcam.v11i1.30.
163. Abdelgadir H.A., Van Staden J. Ethnobotany, ethnopharmacology and toxicity of *Jatropha curcas* L. (Euphorbiaceae): A review. *South African Journal of Botany.* 2013; 88: 204–218.
164. Ayele T.T. A review on traditionally used medicinal plants/herbs for cancer therapy in Ethiopia: Current status, challenge and future perspectives. *Organic Chemistry: Current Research.*; 07. Epub ahead of print 2018. DOI: 10.4172/2161-0401.1000192.
165. Elshamy A.I., Mohamed T.A., Swapana N., Yoneyama T., Noji M., Efferth T., Hegazy M-E.F., Umeyama A. Cytotoxic polyoxygenated isopimarane diterpenoids from the edible rhizomes of *Kaempferia galanga* (kencur). *Industrial Crops and Products.* 2020; 158: 112965.
166. Khairullah A.R., Solikhah T.I., Ansori A.N.M., Hanisia R.H., Puspitarani G.A., Fadholly A., Ramandinianto S.C. Medicinal importance of *Kaempferia galanga* L. (Zingiberaceae): A comprehensive review. *Journal of Hermed Pharmacology.* 2021; 10: 281–288.
167. Kobayashi H., Suzuki R., Sato K., Ogami T., Tomozawa H., Tsubata M., Ichinose K., Aburada M., Ochiai W., Sugiyama K., Shimada T. Effect of *Kaempferia parviflora* extract on knee osteoarthritis. *Journal of Natural Medicines.* 2018; 72: 136–144.
168. Petsophonsakul P., Pompimon W., Banjerpongchai R. Apoptosis induction in human leukemic promyelocytic HL-60 and monocytic U937 cell lines by goniotalamin. *Asian Pacific Journal of Cancer Prevention.* 2013; 14: 2885–2889.
169. Laghezza Masci V., Ovidi E., Taddei A.R., Turchetti G., Tiezzi A., Giacomello P., Garzoli S. Apoptotic effects on HL60 human leukaemia cells induced by Lavandin essential oil treatment. *Molecules.* 2020; 25: 538.
170. Avato P., Migoni D., Argentieri M., Fanizzi F.P., Tava A. Activity of saponins from *Medicago* species against HeLa and MCF-7 cell lines and their capacity to potentiate cisplatin effect. *Anti-Cancer Agents in Medicinal Chemistry.*; 17. Epub ahead of print 24 November 2017. DOI: 10.2174/1871520617666170727152805.
171. Bora K.S., Sharma A. Phytochemical and pharmacological potential of *Medicago sativa*: A review. *Pharmaceutical Biology.* 2011; 49: 211–220.
172. Gatouillat G., Magid A.A., Bertin E., El btaouri H., Morjani H., Lavaud C., Madoulet C. Medicarpin and millepurpan, two flavonoids isolated from *Medicago sativa*, induce apoptosis and overcome multidrug resistance in leukemia P388 cells. *Phytomedicine.* 2015; 22: 1186–1194.
173. Pandey S., Shenmare K. Review on nutritional profile of *Medicago sativa* seeds. *Asian Journal of Advances in Research.* 2021; 261–264.
174. Rosenthal G.A., Nkomo P. The natural abundance of L-canavanine, an active anticancer agent, in alfalfa, *Medicago sativa* (L.). *Pharmaceutical Biology.* 2000; 38: 1–6.
175. Kumar K.S., Bhowmik D. Traditional medicinal uses and therapeutic benefits of *Momordica charantia* Linn. *International Journal of Pharmaceutical Sciences Review and Research.* 2010; 4: 23–28.
176. Saengsai J., Kongtunjanphuk S., Yoswatthana N., Kummalue T., Jiratchariyakul W. Antibacterial and antiproliferative activities of plumericin, an iridoid isolated from *Momordica charantia* vine. *Evidence-Based Complementary and Alternative Medicine.* 2015; 2015: 1–10.
177. Vergara-Jimenez M., Almatrafi M., Fernandez M. Bioactive components in *Moringa oleifera* leaves protect against chronic disease. *Antioxidants.* 2017; 6: 91.
178. Kadam R.A., Dhupal N.D., Khyade V.B. The mulberry, *Morus alba* (L.): The medicinal herbal source for human health. *International*

- Journal of Current Microbiology and Applied Sciences. 2019; 8: 2941–2964.
179. Marwat S.K., Khan M.S., Ghulam S., Anwar N., Mustafa G., Usman K. Phytochemical constituents and pharmacological activities of sweet Basil-*Ocimum basilicum* L.(Lamiaceae). *Asian Journal of Chemistry*. 2011; 23: 3773–3782.
 180. Sharopov F.S., Satyal P., Ali N.A.A., Pokharel S., Zhang H., Wink M., Kukaniev M.A., Setzer W.N. The essential oil compositions of *Ocimum basilicum* from three different regions: Nepal, Tajikistan, and Yemen. *Chemistry & Biodiversity*. 2016; 13: 241–248.
 181. Fares R., Bazzi S., Baydoun S.E., Abdel-Massih R.M. The antioxidant and anti-proliferative activity of the Lebanese *Olea europaea* extract. *Plant Foods for Human Nutrition*. 2011; 66: 58–63.
 182. Asmaa M.J.S., Al-Jamal H.A.N., Ang C.Y., Asan J.M., Seeni A., Johan M.F. Apoptosis induction in MV4-11 and K562 human leukemic cells by *Pereskia scharosa* (Cactaceae) leaf crude extract. *Asian Pacific Journal of Cancer Prevention*. 2014; 15: 475–481.
 183. Kim W.-J., Veriansyah B., Lee Y.-W., Kim J., Kim J.-D. Extraction of mangiferin from Mahkota Dewa (*Phaleria macrocarpa*) using subcritical water. *Journal of Industrial and Engineering Chemistry*. 2010; 16: 425–430.
 184. Winarno H., Katrin W E. Benzophenone glucoside isolated from the ethyl acetate extract of the bark of mahkota dewa [*Phaleria macrocarpa* (Scheff.) Boerl.] and its inhibitory activity on leukemia L1210 cell line. *Indonesian Journal of Chemistry*. 2010; 9: 142–145.
 185. Lee N.Y.S., Khoo W.K.S., Adnan M.A., Mahalingam T.P., Fernandez A.R., Jeevaratnam K. The pharmacological potential of *Phyllanthus niruri*. *Journal of Pharmacy and Pharmacology*. 2016; 68: 953–969.
 186. Singh M., Tiwari N., Shanker K., Verma R.K., Gupta A.K., Gupta M.M. Two new lignans from *Phyllanthus amarus*. *Journal of Asian Natural Products Research*. 2009; 11: 562–568.
 187. Chiang L.-C., Chiang W., Chang M.-Y., Lin C.-C. In vitro cytotoxic, antiviral and immunomodulatory effects of *Plantago major* and *Plantago asiatica*. *The American Journal of Chinese Medicine*. 2003; 31: 225–234.
 188. Velasco-Lezama R., Tapia-Aguilar R., Román-Ramos R., Vega-Avila E., Pérez-Gutiérrez MS. Effect of *Plantago major* on cell proliferation in vitro. *Journal of Ethnopharmacology*. 2006; 103: 36–42.
 189. Woo H.J., Jun D.Y., Lee J.Y., Woo M.H., Yang C.H., Kim Y.H. Apoptogenic activity of 2 α ,3 α -dihydroxyurs-12-ene-28-oic acid from *Prunella vulgaris* var. *lilacina* is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. *Journal of Ethnopharmacology*. 2011; 135: 626–635.
 190. Mnayer D., Fabiano-Tixier A.-S., Petitcolas E., Hamieh T., Nehme N., Ferrant C., Fernandez X., Chemat F. Chemical composition, antibacterial and antioxidant activities of six essential oils from the Alliaceae family. *Molecules*. 2014; 19: 20034–20053.
 191. Sukari M.A., Utami R., Neoh B.K., Ee G.C.L., Jusoh S., Nor S.M.M., Rahmani M. Antileukemic properties of *Spermacoce* species. *Asian Journal of Chemistry*. 2013; 25: 4595–4598.
 192. Labsi M., Khelifi L., Mezioug D., Soufli I., Touil-Boukoffa C. Antihydatic and immunomodulatory effects of *Punica granatum* peel aqueous extract in a murine model of echinococcosis. *Asian Pacific Journal of Tropical Medicine*. 2016; 9: 211–220.
 193. Lansky E.P., Newman R.A. *Punica granatum* (pomegranate) and its potential for prevention and treatment of inflammation and cancer. *Journal of Ethnopharmacology*. 2007; 109: 177–206.
 194. Zhou J., Xu X.-Z., Hu Y.-R., Hu A.-R., Zhu C.-L., Gao G.-S. Cryptotanshinone induces inhibition of breast tumor growth by cytotoxic CD4+ T cells through the JAK2/STAT4/ perforin pathway. *Asian Pacific Journal of Cancer Prevention*. 2014; 15: 2439–2445.
 195. Asadipour M., Malek-Hosseini S., Amirghofran Z. Anti-leukemic activity of *Satureja bachtiarica* occurs by apoptosis in human cells. *Biotechnic & Histochemistry*. 2020; 95: 506–513.
 196. Asadipour M., Amirghofran Z. *Satureja hortensis* induces cell death and inhibited cell cycle progression in K562 myelogenous and Jurkat T cell leukemia cell lines. *Journal of Immunoassay and Immunochemistry*. 2019; 40: 459472.
 197. Lim Y., Rajabalaya R., Lee S., Tennakoon K., Le Q.-V., Idris A., Zulkipli I., Keasberry N., David S. Parasitic mistletoes of the genera *Scurrula* and *Viscum*: From bench to bedside. *Molecules*. 2016; 21: 1048.
 198. Baylor N.W., Fu T., Yan Y.-D., Ruscetti F.W. Inhibition of human T cell leukemia virus by the plant flavonoid baicalin (7-glucuronic acid, 5,6-dihydroxyflavone). *Journal of Infectious Diseases*. 1992; 165: 433–437.
 199. Özmen A., Madlener S., Bauer S., Krasteva S., Vonach C., Giessrigl B., Gridling M., Viola K., Stark N., Saiko P., Michel B., Fritzer-Szekeres M., Szekeres T., Askin-Celik T., Krenn L., Krupitza G. In vitro anti-leukemic activity of the ethno-pharmacological plant *Scutellaria orientalis* ssp. *carica* endemic to western Turkey. *Phytomedicine*. 2010; 17: 55–62.
 200. Biba V., Kunjiraman S., Rajam S.S.N., Anil S. The apoptotic properties of leaf extracts of *Simarouba glauca* against human leukemic cancer cells. *Asian Pacific Journal of Cancer Prevention*. 2021; 22: 1305–1312.
 201. Krishna P.M., KNV R., S S., Banji D. A review on phytochemical, ethnomedical and pharmacological studies on genus *Sophora*, Fabaceae. *Revista Brasileira de Farmacognosia*. 2012; 22: 1145–1154.
 202. Liu X.-S., Jiang J. Molecular mechanism of matrine-induced apoptosis in leukemia K562 cells. *The American Journal of Chinese Medicine*. 2006; 34: 1095–1103.
 203. Mahood H.E., Abbas M.K., Zahid N.A. Micropropagation of feverfew (*Tanacetum parthenium*) and quantification of parthenolide content in its micropropagated and conventionally grown plants. *Horticulturae*. 2022; 8: 50.
 204. Zarshenas M.M., Krenn L. A critical overview on *Thymus daenensis* Celak.: phytochemical and pharmacological investigations. *Journal of Integrative Medicine*. 2015; 13: 91–98.
 205. Mittal J., Sharma M.M., Batra A. *Tinospora cordifolia*: a multipurpose medicinal plant- A review. *Journal of Medicinal Plants*. 2014; 2: 32–47.
 206. Gu J.-Q., Gills J.J., Park E.J., Mata-Greenwood E., Hawthorne M.E., Axelrod F., Chavez P.I., Fong H.H.S., Mehta R.G., Pezzuto J.M., Kinghorn A.D. Sesquiterpenoids from *Tithonia diversifolia* with potential cancer chemopreventive activity. *Journal of Natural Products*. 2002; 65: 532–536.
 207. Aasim M., Baloch F.S., Nadeem M.A., Bakhsh A., Sameeullah M., Day S. Fenugreek (*Trigonella foenum-graecum* L.): An underutilized edible plant of modern world. In: *Global Perspectives on Underutilized Crops*. Cham: Springer International Publishing. 2018; 381–408.
 208. El Bairi K., Ouzir M., Agnieszka N., Khalki L. Anticancer potential of *Trigonella foenum-graecum*: Cellular and molecular targets. *Biomedicine & Pharmacotherapy*. 2017; 90: 479–491.
 209. Diab K.A., Fahmy M.A., Hassan E.M., El-Toumy S.A. Evaluation of the cytotoxic, anticancer, and genotoxic activities of *Acacia nilotica* flowers and their effects on N-methyl-N-nitrosourea-induced genotoxicity in mice. *Molecular Biology Reports*. 2022; 49: 8439–8448.
 210. Sundarraj S., Thangam R., Sreevani V., Kaveri K., Gunasekaran P., Achiraman S., Kannan S. γ -Sitosterol from *Acacia nilotica* L. induces G2/M cell cycle arrest and apoptosis through c-Myc suppression in MCF-7 and A549 cells. *Journal of Ethnopharmacology*. 2012; 141: 803–809.
 211. Mandal C., Dutta A., Mallick A., Chandra S., Misra L., Sangwan R.S., Mandal C. Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. *Apoptosis*. 2008; 13: 1450–1464.
 212. Oh J.H., Lee T.-J., Kim S.H., Choi Y.H., Lee S.H., Lee J.M., Kim Y.-H., Park J.-W., Kwon T.K. Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. *Apoptosis*. 2008; 13: 1494–1504.
 213. Patel K., Singh R.B., Patel D.K. Pharmacological and analytical aspects of withaferin A: A concise report of current scientific literature. *Asian Pacific Journal of Reproduction*. 2013; 2: 238–243.
 214. Turrini E., Calcabrini C., Sestili P., Catanzaro E., De Gianni E., Diaz A., Hrelia P., Tacchini M., Guerrini A., Canonico B., Papa S., Valdrè G., Fimognari C. *Withania somnifera* induces cytotoxic and cytostatic effects on human T leukemia cells. *Toxins*. 2016; 8: 147.